data_7bw5_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 7bw5 _Structure_validation_residue.Date_analyzed 2020-09-04 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.229 0 N-CA-C 112.706 -0.158 . . . . 0.0 112.706 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -85.07 -84.5 0.0 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.765 2.31 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.34 94.79 9.89 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.772 0.32 . . . . 0.0 110.923 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -161.45 -168.37 23.24 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.682 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.34 -7.04 17.9 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.613 0.244 . . . . 0.0 111.436 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -109.74 89.85 8.27 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-N 116.607 -0.269 . . . . 0.0 110.765 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_exo -43.07 121.68 2.46 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.799 2.333 . . . . 0.0 112.749 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -138.68 -57.42 0.63 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.113 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 12.5 t -144.75 32.31 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.163 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.89 -102.37 0.18 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.512 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -98.45 -35.2 10.35 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.81 0.338 . . . . 0.0 110.763 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.31 172.62 26.69 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.667 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 20.9 ttp180 . . . . . 0 C--N 1.33 -0.28 0 CA-C-O 120.815 0.341 . . . . 0.0 110.841 -179.938 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.582 -0.207 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -72.74 -90.2 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.384 0 C-N-CA 122.406 2.07 . . . . 0.0 112.326 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.49 84.71 5.99 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.655 0.264 . . . . 0.0 111.033 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -152.26 -163.63 11.72 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.698 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -109.2 -7.83 15.22 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.582 0.23 . . . . 0.0 111.485 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -111.0 84.45 4.39 Favored Pre-proline 0 C--N 1.331 -0.206 0 CA-C-O 120.711 0.291 . . . . 0.0 110.748 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -43.42 110.59 0.19 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.811 2.341 . . . . 0.0 112.909 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -132.55 -46.48 0.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.789 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 44.8 t -148.58 54.01 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.936 179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 146.63 -103.3 0.27 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.416 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -102.6 -33.25 9.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.873 0.368 . . . . 0.0 110.644 179.773 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.41 166.69 15.92 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.624 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 9.9 ttm180 . . . . . 0 C--N 1.329 -0.325 0 CA-C-O 120.814 0.34 . . . . 0.0 111.052 -179.895 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.255 0 N-CA-C 112.679 -0.168 . . . . 0.0 112.679 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -73.48 -90.92 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 122.497 2.131 . . . . 0.0 112.433 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.39 85.33 6.15 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 120.775 0.322 . . . . 0.0 111.175 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.41 -159.29 8.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.55 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 13.8 p30 -111.59 -19.25 12.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.657 0.265 . . . . 0.0 111.325 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -109.4 92.78 12.21 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.784 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -44.18 137.14 7.66 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.797 2.331 . . . . 0.0 112.723 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -157.75 -44.01 0.06 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.954 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.6 p -149.46 41.41 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.05 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.53 -95.75 0.15 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.395 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -112.64 -37.1 5.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.807 0.337 . . . . 0.0 110.711 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.39 159.06 14.2 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.652 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 42.5 ptt85 . . . . . 0 C--N 1.33 -0.27 0 CA-C-O 120.872 0.367 . . . . 0.0 110.976 179.92 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.272 0 CA-C-O 120.368 -0.129 . . . . 0.0 112.844 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -74.75 -88.04 0.0 OUTLIER 'Trans proline' 0 CA--C 1.531 0.365 0 C-N-CA 122.578 2.186 . . . . 0.0 112.527 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.16 85.42 6.26 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.836 0.35 . . . . 0.0 111.062 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -152.84 -175.93 24.85 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.644 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.403 ' O ' ' CD1' ' A' ' 6' ' ' PHE . 15.3 m-20 -107.0 29.28 7.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.845 0.355 . . . . 0.0 110.991 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.403 ' CD1' ' O ' ' A' ' 5' ' ' ASP . 6.6 m-85 -149.72 87.87 5.03 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.619 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_exo -43.81 106.46 0.08 OUTLIER 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.701 2.267 . . . . 0.0 112.712 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -126.82 -45.17 1.61 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.9 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 44.6 t -155.5 59.35 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.906 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.58 -99.19 0.21 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.384 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -108.93 -31.96 7.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.741 0.305 . . . . 0.0 110.749 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.32 164.4 13.35 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.735 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 4.7 ttp85 . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.327 . . . . 0.0 110.875 -179.997 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 N-CA-C 112.622 -0.191 . . . . 0.0 112.622 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -72.71 -90.38 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.408 0 C-N-CA 122.414 2.076 . . . . 0.0 112.288 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 4.9 ttpt -90.21 84.66 6.11 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.729 0.3 . . . . 0.0 111.027 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.01 -158.43 7.82 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.635 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -114.06 -16.71 12.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.554 0.216 . . . . 0.0 111.345 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -109.33 91.13 9.28 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 120.679 0.276 . . . . 0.0 110.806 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_exo -43.23 114.52 0.47 Allowed 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.843 2.362 . . . . 0.0 112.846 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -134.33 -44.84 0.77 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 50.0 t -145.15 54.82 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.777 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 137.68 -92.62 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.317 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -105.56 -40.99 5.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.814 0.34 . . . . 0.0 110.695 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.76 167.6 18.2 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.686 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 7.7 ptt-85 . . . . . 0 C--N 1.33 -0.245 0 CA-C-O 120.755 0.312 . . . . 0.0 110.766 179.945 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.586 -0.205 . . . . 0.0 112.586 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -88.34 -77.72 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.872 2.381 . . . . 0.0 112.422 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -90.14 96.11 10.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.785 0.326 . . . . 0.0 111.049 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -170.06 -161.81 21.22 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.515 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -125.93 27.6 6.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.798 0.332 . . . . 0.0 111.076 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.07 93.53 4.73 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.631 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_exo -43.18 121.43 2.42 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.73 2.287 . . . . 0.0 112.86 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -143.17 -45.81 0.3 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.82 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . 0.425 ' O ' ' CG1' ' A' ' 9' ' ' VAL . 44.4 t -156.13 38.57 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.077 0.465 . . . . 0.0 110.619 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 163.79 -107.97 0.32 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.364 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -101.5 -30.89 11.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.776 0.322 . . . . 0.0 110.824 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.7 165.67 15.18 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.811 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 12.9 ptt180 . . . . . 0 C--N 1.33 -0.274 0 CA-C-O 120.727 0.298 . . . . 0.0 110.993 179.957 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 0.188 0 N-CA-C 112.626 -0.189 . . . . 0.0 112.626 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -74.73 -93.03 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.454 2.103 . . . . 0.0 112.522 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 ttpt -90.23 86.47 6.53 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.774 0.321 . . . . 0.0 111.159 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.0 -145.68 4.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.467 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -118.95 -25.4 6.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.583 0.23 . . . . 0.0 111.573 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -119.1 106.0 43.95 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.048 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.43 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 87.4 Cg_exo -46.44 112.95 0.53 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.639 2.226 . . . . 0.0 112.677 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -118.52 -45.35 2.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.855 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.7 t -155.46 54.53 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.766 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.93 -84.35 0.16 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.345 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -121.39 -40.03 2.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.712 0.292 . . . . 0.0 110.776 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.43 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 160.79 167.08 20.77 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.865 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.3 ptt180 . . . . . 0 C--N 1.33 -0.242 0 CA-C-O 120.758 0.313 . . . . 0.0 110.9 179.882 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.358 -0.297 . . . . 0.0 112.358 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.75 -94.35 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.391 0 C-N-CA 122.344 2.029 . . . . 0.0 112.174 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 11.1 ttmm -90.53 86.14 6.33 Favored 'General case' 0 C--N 1.333 -0.111 0 CA-C-O 120.714 0.292 . . . . 0.0 111.09 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.11 -155.89 6.63 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.609 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -111.75 -21.82 11.46 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.599 0.238 . . . . 0.0 111.352 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -108.99 92.96 11.62 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.908 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . 0.405 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 80.2 Cg_exo -45.39 119.18 2.47 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.744 2.296 . . . . 0.0 112.793 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -135.83 -47.27 0.67 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.713 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.9 t -136.81 31.64 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.691 179.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.56 -102.28 0.21 Allowed Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.346 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.88 -33.53 11.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.776 0.322 . . . . 0.0 110.604 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.405 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 157.09 164.47 13.66 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.779 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.256 0 CA-C-O 120.748 0.308 . . . . 0.0 110.764 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.602 -0.199 . . . . 0.0 112.602 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -74.16 -92.98 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.435 0 C-N-CA 122.494 2.129 . . . . 0.0 112.351 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -90.42 86.53 6.48 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.799 0.333 . . . . 0.0 111.006 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.2 -154.49 6.23 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.619 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -116.44 -18.2 10.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.579 0.228 . . . . 0.0 111.435 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -106.6 98.08 19.2 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.6 0.238 . . . . 0.0 110.888 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -48.04 112.2 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.515 2.144 . . . . 0.0 112.673 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -134.5 -43.99 0.76 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.872 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 49.1 t -155.55 56.8 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.923 179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 145.2 -104.9 0.33 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.564 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -104.4 -31.28 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.329 . . . . 0.0 110.976 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 164.9 162.68 16.46 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.545 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 11.1 ttp-105 . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.863 0.363 . . . . 0.0 111.059 -179.884 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.203 0 N-CA-C 112.587 -0.205 . . . . 0.0 112.587 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -75.21 -92.27 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.517 2.145 . . . . 0.0 112.449 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.41 86.79 6.55 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-O 120.689 0.28 . . . . 0.0 111.164 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.49 -155.13 6.32 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.567 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -112.83 -22.38 10.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.679 0.276 . . . . 0.0 111.267 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.415 ' CD2' ' N ' ' A' ' 6' ' ' PHE . 4.9 m-85 -112.36 98.67 44.24 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.909 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_exo -47.55 116.06 1.67 Allowed 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.631 2.221 . . . . 0.0 112.647 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -127.05 -45.0 1.58 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.82 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.5 p -157.81 50.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.068 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.19 -98.86 0.17 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.392 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -124.35 5.12 8.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.567 0.222 . . . . 0.0 111.302 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.67 153.57 7.88 Favored Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.749 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.6 ptm180 . . . . . 0 C--N 1.33 -0.26 0 CA-C-O 120.806 0.336 . . . . 0.0 110.79 179.786 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 N-CA-C 112.703 -0.159 . . . . 0.0 112.703 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -80.07 -92.6 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.438 0 C-N-CA 122.624 2.216 . . . . 0.0 112.438 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.43 91.37 8.43 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.743 0.306 . . . . 0.0 111.083 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.84 -152.75 5.7 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.538 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -112.27 -24.45 9.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.682 0.277 . . . . 0.0 111.204 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -110.66 91.0 11.43 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.776 -179.783 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -44.47 96.28 0.03 OUTLIER 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.743 2.296 . . . . 0.0 112.642 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -96.83 -46.07 6.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.7 p -146.41 41.25 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.039 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.01 -90.68 0.11 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.516 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -108.26 -31.46 7.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.815 0.34 . . . . 0.0 110.891 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.01 170.35 14.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.741 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.1 ptm180 . . . . . 0 C--N 1.33 -0.272 0 CA-C-O 120.83 0.348 . . . . 0.0 110.924 -179.975 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.783 -0.127 . . . . 0.0 112.783 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -79.59 -91.08 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.451 0 C-N-CA 122.562 2.175 . . . . 0.0 112.592 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.43 90.17 7.91 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.679 0.276 . . . . 0.0 111.237 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.81 -155.36 6.5 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.42 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . 0.405 ' OD2' ' CE2' ' A' ' 6' ' ' PHE . 1.4 p30 -112.37 -23.26 10.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.785 0.326 . . . . 0.0 111.12 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.405 ' CE2' ' OD2' ' A' ' 5' ' ' ASP . 17.9 m-85 -108.45 96.0 17.77 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.035 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -47.83 110.06 0.28 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.519 2.146 . . . . 0.0 112.44 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -115.51 -43.9 3.01 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.999 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 12.7 p -157.84 34.77 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.059 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 178.05 -100.59 0.14 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.504 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -111.11 -28.71 8.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.714 0.293 . . . . 0.0 111.05 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.04 163.68 22.4 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.862 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.255 0 CA-C-O 120.841 0.353 . . . . 0.0 110.931 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.209 0 N-CA-C 112.652 -0.179 . . . . 0.0 112.652 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.42 -93.63 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.447 0 C-N-CA 122.58 2.187 . . . . 0.0 112.228 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.61 91.13 8.29 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.775 0.322 . . . . 0.0 111.098 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.07 -159.09 8.38 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.471 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.47 -20.92 12.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.649 0.261 . . . . 0.0 111.189 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -111.31 92.76 16.7 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.726 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -45.39 127.82 9.6 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.694 2.263 . . . . 0.0 112.665 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -139.81 -46.05 0.44 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.938 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.8 p -147.55 38.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.971 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 162.08 -90.15 0.11 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.491 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.54 -39.19 3.37 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.857 0.36 . . . . 0.0 110.778 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.53 160.77 20.85 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.592 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.26 0 CA-C-O 120.871 0.367 . . . . 0.0 110.948 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 CA-C-O 120.351 -0.138 . . . . 0.0 112.781 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -75.58 -90.66 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.42 0 C-N-CA 122.566 2.178 . . . . 0.0 112.504 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -90.38 86.74 6.55 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.738 0.304 . . . . 0.0 111.179 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.05 -158.87 8.27 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.54 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -112.02 -17.11 12.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.566 0.222 . . . . 0.0 111.343 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -108.69 92.67 10.67 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.896 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_exo -46.4 116.45 1.56 Allowed 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.547 2.165 . . . . 0.0 112.63 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -131.95 -45.58 0.95 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.927 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 12.1 p -154.65 46.21 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.985 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 161.81 -103.12 0.22 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.323 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -110.06 -25.97 9.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.725 0.298 . . . . 0.0 110.907 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.56 162.7 12.4 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.691 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.28 0 CA-C-O 120.749 0.309 . . . . 0.0 110.811 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.255 0 N-CA-C 112.758 -0.137 . . . . 0.0 112.758 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' PRO . . . . . 0.428 ' O ' ' N ' ' A' ' 12' ' ' GLY . 60.2 Cg_endo -75.67 -91.07 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.595 2.197 . . . . 0.0 112.565 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 ttpt -90.52 86.73 6.5 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.621 0.248 . . . . 0.0 111.15 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -137.23 -97.56 0.46 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.625 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -171.32 -37.77 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.892 0.377 . . . . 0.0 110.715 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -105.65 97.46 14.68 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.435 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -40.92 111.18 0.14 Allowed 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 122.902 2.402 . . . . 0.0 112.957 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -116.08 -47.17 2.78 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.859 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 29.2 t -155.61 41.9 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.859 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.83 -81.73 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.531 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -128.95 -45.48 1.27 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.808 0.337 . . . . 0.0 110.928 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 2' ' ' PRO . . . -176.79 154.03 15.29 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.687 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 111.041 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.229 0 N-CA-C 112.706 -0.158 . . . . 0.0 112.706 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -85.07 -84.5 0.0 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.765 2.31 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.34 94.79 9.89 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.772 0.32 . . . . 0.0 110.923 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -161.45 -168.37 23.24 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.682 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.34 -7.04 17.9 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.613 0.244 . . . . 0.0 111.436 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -109.74 89.85 8.27 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-N 116.607 -0.269 . . . . 0.0 110.765 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_exo -43.07 121.68 2.46 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.799 2.333 . . . . 0.0 112.749 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -138.68 -57.42 0.63 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.113 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 12.5 t -144.75 32.31 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.163 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.89 -102.37 0.18 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.512 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -98.45 -35.2 10.35 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.81 0.338 . . . . 0.0 110.763 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.31 172.62 26.69 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.667 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 20.9 ttp180 -116.93 165.54 13.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.815 0.341 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 29.3 pt -115.85 -37.32 2.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.112 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 63.5 tp -122.8 143.53 49.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.8 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.28 51.26 1.68 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.136 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.379 -1.234 . . . . 0.0 112.464 179.948 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.582 -0.207 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -72.74 -90.2 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.384 0 C-N-CA 122.406 2.07 . . . . 0.0 112.326 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.49 84.71 5.99 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.655 0.264 . . . . 0.0 111.033 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -152.26 -163.63 11.72 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.698 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -109.2 -7.83 15.22 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.582 0.23 . . . . 0.0 111.485 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -111.0 84.45 4.39 Favored Pre-proline 0 C--N 1.331 -0.206 0 CA-C-O 120.711 0.291 . . . . 0.0 110.748 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -43.42 110.59 0.19 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.811 2.341 . . . . 0.0 112.909 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -132.55 -46.48 0.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.789 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 44.8 t -148.58 54.01 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.936 179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 146.63 -103.3 0.27 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.416 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -102.6 -33.25 9.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.873 0.368 . . . . 0.0 110.644 179.773 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.41 166.69 15.92 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.624 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 9.9 ttm180 -98.41 141.67 30.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.814 0.34 . . . . 0.0 111.052 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 1.4 pp -113.59 -27.46 2.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.155 179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -128.95 81.7 2.04 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.754 179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -94.77 46.08 1.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.132 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.029 0 CA-C-O 118.356 -1.246 . . . . 0.0 112.499 -179.975 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.255 0 N-CA-C 112.679 -0.168 . . . . 0.0 112.679 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -73.48 -90.92 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 122.497 2.131 . . . . 0.0 112.433 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.39 85.33 6.15 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 120.775 0.322 . . . . 0.0 111.175 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.41 -159.29 8.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.55 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 13.8 p30 -111.59 -19.25 12.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.657 0.265 . . . . 0.0 111.325 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -109.4 92.78 12.21 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.784 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.7 Cg_exo -44.18 137.14 7.66 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.797 2.331 . . . . 0.0 112.723 -179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -157.75 -44.01 0.06 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.954 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.6 p -149.46 41.41 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.05 179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.53 -95.75 0.15 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.395 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -112.64 -37.1 5.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.807 0.337 . . . . 0.0 110.711 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 169.39 159.06 14.2 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.652 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 42.5 ptt85 -107.48 -172.87 2.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.872 0.367 . . . . 0.0 110.976 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 9.2 pt -138.82 -42.94 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.258 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.9 mm? -92.4 151.9 20.0 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.881 179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -104.86 -32.27 8.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.09 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.402 -1.221 . . . . 0.0 112.523 179.986 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.272 0 CA-C-O 120.368 -0.129 . . . . 0.0 112.844 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -74.75 -88.04 0.0 OUTLIER 'Trans proline' 0 CA--C 1.531 0.365 0 C-N-CA 122.578 2.186 . . . . 0.0 112.527 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.16 85.42 6.26 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.836 0.35 . . . . 0.0 111.062 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -152.84 -175.93 24.85 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.644 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.403 ' O ' ' CD1' ' A' ' 6' ' ' PHE . 15.3 m-20 -107.0 29.28 7.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.845 0.355 . . . . 0.0 110.991 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.403 ' CD1' ' O ' ' A' ' 5' ' ' ASP . 6.6 m-85 -149.72 87.87 5.03 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.619 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_exo -43.81 106.46 0.08 OUTLIER 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.701 2.267 . . . . 0.0 112.712 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -126.82 -45.17 1.61 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.9 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 44.6 t -155.5 59.35 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.906 179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.58 -99.19 0.21 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.384 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -108.93 -31.96 7.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.741 0.305 . . . . 0.0 110.749 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.32 164.4 13.35 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.735 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 4.7 ttp85 -115.95 173.12 6.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.327 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.432 ' N ' ' CD1' ' A' ' 14' ' ' ILE . 0.2 OUTLIER -143.43 28.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.181 179.955 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -127.26 163.82 23.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.818 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.3 -67.39 0.45 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.112 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.114 0 CA-C-O 118.41 -1.217 . . . . 0.0 112.515 -179.951 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 N-CA-C 112.622 -0.191 . . . . 0.0 112.622 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -72.71 -90.38 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.408 0 C-N-CA 122.414 2.076 . . . . 0.0 112.288 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 4.9 ttpt -90.21 84.66 6.11 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.729 0.3 . . . . 0.0 111.027 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.01 -158.43 7.82 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.635 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -114.06 -16.71 12.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.554 0.216 . . . . 0.0 111.345 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -109.33 91.13 9.28 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 120.679 0.276 . . . . 0.0 110.806 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 93.7 Cg_exo -43.23 114.52 0.47 Allowed 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.843 2.362 . . . . 0.0 112.846 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.3 p-10 -134.33 -44.84 0.77 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 50.0 t -145.15 54.82 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.777 179.735 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 137.68 -92.62 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.317 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -105.56 -40.99 5.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.814 0.34 . . . . 0.0 110.695 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.76 167.6 18.2 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.686 179.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 7.7 ptt-85 -106.8 154.58 20.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.755 0.312 . . . . 0.0 110.766 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 7.9 tp -93.4 -30.9 4.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.193 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.4 mt -108.48 141.15 40.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.927 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.93 81.93 1.38 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.096 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.031 0 CA-C-O 118.369 -1.24 . . . . 0.0 112.493 -180.0 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.586 -0.205 . . . . 0.0 112.586 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -88.34 -77.72 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.872 2.381 . . . . 0.0 112.422 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -90.14 96.11 10.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.785 0.326 . . . . 0.0 111.049 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -170.06 -161.81 21.22 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.515 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -125.93 27.6 6.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.798 0.332 . . . . 0.0 111.076 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.07 93.53 4.73 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.631 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_exo -43.18 121.43 2.42 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.73 2.287 . . . . 0.0 112.86 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -143.17 -45.81 0.3 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.82 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . 0.425 ' O ' ' CG1' ' A' ' 9' ' ' VAL . 44.4 t -156.13 38.57 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.077 0.465 . . . . 0.0 110.619 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 163.79 -107.97 0.32 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.364 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -101.5 -30.89 11.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.776 0.322 . . . . 0.0 110.824 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.7 165.67 15.18 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.811 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 12.9 ptt180 -126.57 160.17 31.4 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.727 0.298 . . . . 0.0 110.993 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . 0.432 ' N ' ' CD1' ' A' ' 14' ' ' ILE . 0.2 OUTLIER -155.51 25.72 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.301 179.803 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.4 mt -141.59 57.24 1.51 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.977 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.87 68.9 7.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.134 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.341 -1.255 . . . . 0.0 112.515 179.934 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 0.188 0 N-CA-C 112.626 -0.189 . . . . 0.0 112.626 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -74.73 -93.03 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.454 2.103 . . . . 0.0 112.522 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 ttpt -90.23 86.47 6.53 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.774 0.321 . . . . 0.0 111.159 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.0 -145.68 4.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.467 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -118.95 -25.4 6.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.583 0.23 . . . . 0.0 111.573 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -119.1 106.0 43.95 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.048 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.43 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 87.4 Cg_exo -46.44 112.95 0.53 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.639 2.226 . . . . 0.0 112.677 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -118.52 -45.35 2.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.855 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 48.7 t -155.46 54.53 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.766 179.706 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.93 -84.35 0.16 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.345 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -121.39 -40.03 2.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.712 0.292 . . . . 0.0 110.776 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.43 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 160.79 167.08 20.77 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.865 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.3 ptt180 -127.36 152.71 47.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.758 0.313 . . . . 0.0 110.9 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 1.9 pp -128.25 25.96 2.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.254 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -150.06 89.62 1.61 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.872 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -127.32 -76.13 0.57 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.096 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.424 -1.209 . . . . 0.0 112.534 -179.959 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.358 -0.297 . . . . 0.0 112.358 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.75 -94.35 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.391 0 C-N-CA 122.344 2.029 . . . . 0.0 112.174 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 11.1 ttmm -90.53 86.14 6.33 Favored 'General case' 0 C--N 1.333 -0.111 0 CA-C-O 120.714 0.292 . . . . 0.0 111.09 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.11 -155.89 6.63 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.609 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -111.75 -21.82 11.46 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.599 0.238 . . . . 0.0 111.352 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -108.99 92.96 11.62 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.908 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . 0.405 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 80.2 Cg_exo -45.39 119.18 2.47 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.744 2.296 . . . . 0.0 112.793 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.1 p-10 -135.83 -47.27 0.67 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.713 179.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 24.9 t -136.81 31.64 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.691 179.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.56 -102.28 0.21 Allowed Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.346 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.88 -33.53 11.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.776 0.322 . . . . 0.0 110.604 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.405 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 157.09 164.47 13.66 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.779 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.23 135.25 46.95 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.748 0.308 . . . . 0.0 110.764 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 19.7 pt -86.4 -33.26 7.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.25 -179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -103.57 114.71 29.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.923 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -114.35 74.22 0.86 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.013 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.383 -1.231 . . . . 0.0 112.517 -179.969 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.602 -0.199 . . . . 0.0 112.602 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -74.16 -92.98 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.435 0 C-N-CA 122.494 2.129 . . . . 0.0 112.351 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -90.42 86.53 6.48 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.799 0.333 . . . . 0.0 111.006 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.2 -154.49 6.23 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.619 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -116.44 -18.2 10.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.579 0.228 . . . . 0.0 111.435 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -106.6 98.08 19.2 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.6 0.238 . . . . 0.0 110.888 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -48.04 112.2 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.515 2.144 . . . . 0.0 112.673 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -134.5 -43.99 0.76 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.872 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 49.1 t -155.55 56.8 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.923 179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 145.2 -104.9 0.33 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.564 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -104.4 -31.28 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.329 . . . . 0.0 110.976 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 164.9 162.68 16.46 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.545 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 11.1 ttp-105 -106.28 165.95 10.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.863 0.363 . . . . 0.0 111.059 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 2.7 pt -145.08 32.78 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.988 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 13.7 mt -133.1 95.28 3.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.85 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -136.18 116.74 13.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.336 -1.258 . . . . 0.0 112.497 179.979 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.203 0 N-CA-C 112.587 -0.205 . . . . 0.0 112.587 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -75.21 -92.27 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.517 2.145 . . . . 0.0 112.449 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.41 86.79 6.55 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-O 120.689 0.28 . . . . 0.0 111.164 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.49 -155.13 6.32 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.567 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -112.83 -22.38 10.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.679 0.276 . . . . 0.0 111.267 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.415 ' CD2' ' N ' ' A' ' 6' ' ' PHE . 4.9 m-85 -112.36 98.67 44.24 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.909 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_exo -47.55 116.06 1.67 Allowed 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.631 2.221 . . . . 0.0 112.647 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.6 p-10 -127.05 -45.0 1.58 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.82 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.5 p -157.81 50.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.068 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.19 -98.86 0.17 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.392 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -124.35 5.12 8.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.567 0.222 . . . . 0.0 111.302 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.67 153.57 7.88 Favored Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.749 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.6 ptm180 -105.46 152.8 22.56 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.806 0.336 . . . . 0.0 110.79 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 1.1 mp -111.65 -28.99 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.175 179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -107.56 154.43 21.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.829 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -112.11 70.88 0.72 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.085 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.087 0 CA-C-O 118.341 -1.255 . . . . 0.0 112.474 -179.97 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.274 0 N-CA-C 112.703 -0.159 . . . . 0.0 112.703 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -80.07 -92.6 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.438 0 C-N-CA 122.624 2.216 . . . . 0.0 112.438 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.43 91.37 8.43 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.743 0.306 . . . . 0.0 111.083 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.84 -152.75 5.7 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.538 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -112.27 -24.45 9.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.682 0.277 . . . . 0.0 111.204 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -110.66 91.0 11.43 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.776 -179.783 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_exo -44.47 96.28 0.03 OUTLIER 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.743 2.296 . . . . 0.0 112.642 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -96.83 -46.07 6.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.7 p -146.41 41.25 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.039 179.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.01 -90.68 0.11 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.516 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -108.26 -31.46 7.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.815 0.34 . . . . 0.0 110.891 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 145.01 170.35 14.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.741 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.1 ptm180 -115.88 165.68 12.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.83 0.348 . . . . 0.0 110.924 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 1.7 pp -114.92 36.37 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.093 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 33.6 tp -108.19 112.12 24.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.933 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -90.53 52.17 2.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.102 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.355 -1.247 . . . . 0.0 112.517 179.972 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.783 -0.127 . . . . 0.0 112.783 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -79.59 -91.08 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.451 0 C-N-CA 122.562 2.175 . . . . 0.0 112.592 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.43 90.17 7.91 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.679 0.276 . . . . 0.0 111.237 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.81 -155.36 6.5 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.42 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . 0.405 ' OD2' ' CE2' ' A' ' 6' ' ' PHE . 1.4 p30 -112.37 -23.26 10.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.785 0.326 . . . . 0.0 111.12 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.405 ' CE2' ' OD2' ' A' ' 5' ' ' ASP . 17.9 m-85 -108.45 96.0 17.77 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.035 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -47.83 110.06 0.28 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.519 2.146 . . . . 0.0 112.44 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 p30 -115.51 -43.9 3.01 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.999 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 12.7 p -157.84 34.77 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.059 179.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 178.05 -100.59 0.14 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.504 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -111.11 -28.71 8.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.714 0.293 . . . . 0.0 111.05 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.04 163.68 22.4 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.862 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.36 175.04 5.6 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.841 0.353 . . . . 0.0 110.931 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 30.2 mm -114.12 -38.85 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.024 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -122.92 105.58 10.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.899 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -135.1 111.47 9.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.059 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.38 -1.233 . . . . 0.0 112.551 179.984 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.209 0 N-CA-C 112.652 -0.179 . . . . 0.0 112.652 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.42 -93.63 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.447 0 C-N-CA 122.58 2.187 . . . . 0.0 112.228 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.61 91.13 8.29 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.775 0.322 . . . . 0.0 111.098 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.07 -159.09 8.38 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.471 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.47 -20.92 12.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.649 0.261 . . . . 0.0 111.189 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -111.31 92.76 16.7 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.726 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -45.39 127.82 9.6 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.694 2.263 . . . . 0.0 112.665 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.0 p-10 -139.81 -46.05 0.44 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.938 179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 14.8 p -147.55 38.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.971 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 162.08 -90.15 0.11 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.491 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.54 -39.19 3.37 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.857 0.36 . . . . 0.0 110.778 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 171.53 160.77 20.85 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.592 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.93 -179.07 3.59 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.871 0.367 . . . . 0.0 110.948 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 2.2 pp -143.89 27.34 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.126 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.421 ' CD2' ' N ' ' A' ' 15' ' ' LEU . 1.3 pt? -150.03 121.68 8.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.942 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -150.06 -170.27 3.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.11 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.081 0 CA-C-O 118.374 -1.237 . . . . 0.0 112.503 -179.979 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 CA-C-O 120.351 -0.138 . . . . 0.0 112.781 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -75.58 -90.66 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.42 0 C-N-CA 122.566 2.178 . . . . 0.0 112.504 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -90.38 86.74 6.55 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.738 0.304 . . . . 0.0 111.179 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.05 -158.87 8.27 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.54 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -112.02 -17.11 12.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.566 0.222 . . . . 0.0 111.343 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -108.69 92.67 10.67 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.896 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_exo -46.4 116.45 1.56 Allowed 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.547 2.165 . . . . 0.0 112.63 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -131.95 -45.58 0.95 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.927 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 12.1 p -154.65 46.21 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.985 -179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 161.81 -103.12 0.22 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.323 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -110.06 -25.97 9.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.725 0.298 . . . . 0.0 110.907 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.56 162.7 12.4 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.691 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.77 171.17 7.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.749 0.309 . . . . 0.0 110.811 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 7.5 tp -146.43 -45.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.09 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -114.83 121.21 42.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.765 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -107.53 30.79 5.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.196 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.382 -1.232 . . . . 0.0 112.522 179.943 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.255 0 N-CA-C 112.758 -0.137 . . . . 0.0 112.758 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' PRO . . . . . 0.428 ' O ' ' N ' ' A' ' 12' ' ' GLY . 60.2 Cg_endo -75.67 -91.07 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.595 2.197 . . . . 0.0 112.565 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 ttpt -90.52 86.73 6.5 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.621 0.248 . . . . 0.0 111.15 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -137.23 -97.56 0.46 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.625 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -171.32 -37.77 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.892 0.377 . . . . 0.0 110.715 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -105.65 97.46 14.68 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.435 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -40.92 111.18 0.14 Allowed 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 122.902 2.402 . . . . 0.0 112.957 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -116.08 -47.17 2.78 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.859 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' VAL . . . . . . . . . . . . . 29.2 t -155.61 41.9 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.859 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.83 -81.73 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.531 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -128.95 -45.48 1.27 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.808 0.337 . . . . 0.0 110.928 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 2' ' ' PRO . . . -176.79 154.03 15.29 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.687 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.41 174.44 5.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 111.041 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 18.3 mt -132.6 32.34 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.063 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.0 mt -131.99 156.55 46.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -137.33 152.19 49.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.373 -1.237 . . . . 0.0 112.514 179.975 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.229 0 N-CA-C 112.706 -0.158 . . . . 0.0 112.706 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -85.07 -84.5 0.0 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.765 2.31 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.34 94.79 9.89 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.772 0.32 . . . . 0.0 110.923 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -161.45 -168.37 23.24 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.682 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.34 -7.04 17.9 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.613 0.244 . . . . 0.0 111.436 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -109.74 89.85 8.27 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-N 116.607 -0.269 . . . . 0.0 110.765 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_exo -43.07 121.68 2.46 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.799 2.333 . . . . 0.0 112.749 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -138.68 -57.42 0.63 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.113 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 9' ' ' VAL . 12.5 t -144.75 32.31 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.163 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.89 -102.37 0.18 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.512 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -98.45 -35.2 10.35 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.81 0.338 . . . . 0.0 110.763 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.31 172.62 26.69 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.667 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 20.9 ttp180 . . . . . 0 C--N 1.33 -0.28 0 CA-C-O 120.815 0.341 . . . . 0.0 110.841 -179.938 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.582 -0.207 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -72.74 -90.2 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.384 0 C-N-CA 122.406 2.07 . . . . 0.0 112.326 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.49 84.71 5.99 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.655 0.264 . . . . 0.0 111.033 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -152.26 -163.63 11.72 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.698 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -109.2 -7.83 15.22 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.582 0.23 . . . . 0.0 111.485 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -111.0 84.45 4.39 Favored Pre-proline 0 C--N 1.331 -0.206 0 CA-C-O 120.711 0.291 . . . . 0.0 110.748 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -43.42 110.59 0.19 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.811 2.341 . . . . 0.0 112.909 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -132.55 -46.48 0.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.789 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.569 HG12 ' O ' ' A' ' 9' ' ' VAL . 44.8 t -148.58 54.01 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.936 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 146.63 -103.3 0.27 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.416 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -102.6 -33.25 9.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.873 0.368 . . . . 0.0 110.644 179.773 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.41 166.69 15.92 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.624 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 9.9 ttm180 . . . . . 0 C--N 1.329 -0.325 0 CA-C-O 120.814 0.34 . . . . 0.0 111.052 -179.895 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . 0.589 ' HA2' HG12 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.452 -0.255 0 N-CA-C 112.679 -0.168 . . . . 0.0 112.679 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -73.48 -90.92 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 122.497 2.131 . . . . 0.0 112.433 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.39 85.33 6.15 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 120.775 0.322 . . . . 0.0 111.175 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.41 -159.29 8.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.55 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 13.8 p30 -111.59 -19.25 12.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.657 0.265 . . . . 0.0 111.325 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -109.4 92.78 12.21 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.784 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.4 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 88.7 Cg_exo -44.18 137.14 7.66 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.797 2.331 . . . . 0.0 112.723 -179.726 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -157.75 -44.01 0.06 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.954 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.593 ' O ' HG22 ' A' ' 9' ' ' VAL . 14.6 p -149.46 41.41 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.05 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.53 -95.75 0.15 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.395 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -112.64 -37.1 5.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.807 0.337 . . . . 0.0 110.711 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 169.39 159.06 14.2 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.652 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 42.5 ptt85 . . . . . 0 C--N 1.33 -0.27 0 CA-C-O 120.872 0.367 . . . . 0.0 110.976 179.92 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.272 0 CA-C-O 120.368 -0.129 . . . . 0.0 112.844 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -74.75 -88.04 0.0 OUTLIER 'Trans proline' 0 CA--C 1.531 0.365 0 C-N-CA 122.578 2.186 . . . . 0.0 112.527 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.16 85.42 6.26 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.836 0.35 . . . . 0.0 111.062 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -152.84 -175.93 24.85 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.644 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.403 ' O ' ' CD1' ' A' ' 6' ' ' PHE . 15.3 m-20 -107.0 29.28 7.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.845 0.355 . . . . 0.0 110.991 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.403 ' CD1' ' O ' ' A' ' 5' ' ' ASP . 6.6 m-85 -149.72 87.87 5.03 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.619 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_exo -43.81 106.46 0.08 OUTLIER 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.701 2.267 . . . . 0.0 112.712 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -126.82 -45.17 1.61 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.9 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.504 HG12 ' O ' ' A' ' 9' ' ' VAL . 44.6 t -155.5 59.35 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.906 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.58 -99.19 0.21 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.384 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -108.93 -31.96 7.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.741 0.305 . . . . 0.0 110.749 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.32 164.4 13.35 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.735 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 4.7 ttp85 . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.327 . . . . 0.0 110.875 -179.997 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 N-CA-C 112.622 -0.191 . . . . 0.0 112.622 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -72.71 -90.38 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.408 0 C-N-CA 122.414 2.076 . . . . 0.0 112.288 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 4.9 ttpt -90.21 84.66 6.11 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.729 0.3 . . . . 0.0 111.027 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.01 -158.43 7.82 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.635 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -114.06 -16.71 12.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.554 0.216 . . . . 0.0 111.345 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -109.33 91.13 9.28 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 120.679 0.276 . . . . 0.0 110.806 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.434 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 93.7 Cg_exo -43.23 114.52 0.47 Allowed 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.843 2.362 . . . . 0.0 112.846 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.457 ' OD1' HG23 ' A' ' 9' ' ' VAL . 3.3 p-10 -134.33 -44.84 0.77 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.576 HG12 ' O ' ' A' ' 9' ' ' VAL . 50.0 t -145.15 54.82 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.777 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 137.68 -92.62 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.317 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -105.56 -40.99 5.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.814 0.34 . . . . 0.0 110.695 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.434 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 156.76 167.6 18.2 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.686 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 7.7 ptt-85 . . . . . 0 C--N 1.33 -0.245 0 CA-C-O 120.755 0.312 . . . . 0.0 110.766 179.945 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.586 -0.205 . . . . 0.0 112.586 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -88.34 -77.72 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.872 2.381 . . . . 0.0 112.422 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -90.14 96.11 10.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.785 0.326 . . . . 0.0 111.049 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -170.06 -161.81 21.22 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.515 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -125.93 27.6 6.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.798 0.332 . . . . 0.0 111.076 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.07 93.53 4.73 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.631 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_exo -43.18 121.43 2.42 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.73 2.287 . . . . 0.0 112.86 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -143.17 -45.81 0.3 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.82 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.65 HG12 ' O ' ' A' ' 9' ' ' VAL . 44.4 t -156.13 38.57 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.077 0.465 . . . . 0.0 110.619 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 163.79 -107.97 0.32 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.364 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -101.5 -30.89 11.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.776 0.322 . . . . 0.0 110.824 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.7 165.67 15.18 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.811 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 12.9 ptt180 . . . . . 0 C--N 1.33 -0.274 0 CA-C-O 120.727 0.298 . . . . 0.0 110.993 179.957 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 0.188 0 N-CA-C 112.626 -0.189 . . . . 0.0 112.626 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -74.73 -93.03 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.454 2.103 . . . . 0.0 112.522 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 ttpt -90.23 86.47 6.53 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.774 0.321 . . . . 0.0 111.159 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.0 -145.68 4.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.467 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -118.95 -25.4 6.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.583 0.23 . . . . 0.0 111.573 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -119.1 106.0 43.95 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.048 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.483 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 87.4 Cg_exo -46.44 112.95 0.53 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.639 2.226 . . . . 0.0 112.677 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -118.52 -45.35 2.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.855 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.584 HG12 ' O ' ' A' ' 9' ' ' VAL . 48.7 t -155.46 54.53 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.766 179.706 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.93 -84.35 0.16 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.345 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -121.39 -40.03 2.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.712 0.292 . . . . 0.0 110.776 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.483 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 160.79 167.08 20.77 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.865 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.3 ptt180 . . . . . 0 C--N 1.33 -0.242 0 CA-C-O 120.758 0.313 . . . . 0.0 110.9 179.882 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.358 -0.297 . . . . 0.0 112.358 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.75 -94.35 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.391 0 C-N-CA 122.344 2.029 . . . . 0.0 112.174 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 11.1 ttmm -90.53 86.14 6.33 Favored 'General case' 0 C--N 1.333 -0.111 0 CA-C-O 120.714 0.292 . . . . 0.0 111.09 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.11 -155.89 6.63 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.609 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -111.75 -21.82 11.46 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.599 0.238 . . . . 0.0 111.352 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -108.99 92.96 11.62 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.908 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.458 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 80.2 Cg_exo -45.39 119.18 2.47 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.744 2.296 . . . . 0.0 112.793 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.765 ' OD1' HG23 ' A' ' 9' ' ' VAL . 4.1 p-10 -135.83 -47.27 0.67 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.713 179.703 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.765 HG23 ' OD1' ' A' ' 8' ' ' ASP . 24.9 t -136.81 31.64 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.691 179.697 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.56 -102.28 0.21 Allowed Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.346 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.88 -33.53 11.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.776 0.322 . . . . 0.0 110.604 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.458 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 157.09 164.47 13.66 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.779 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.256 0 CA-C-O 120.748 0.308 . . . . 0.0 110.764 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.602 -0.199 . . . . 0.0 112.602 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -74.16 -92.98 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.435 0 C-N-CA 122.494 2.129 . . . . 0.0 112.351 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -90.42 86.53 6.48 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.799 0.333 . . . . 0.0 111.006 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.2 -154.49 6.23 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.619 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -116.44 -18.2 10.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.579 0.228 . . . . 0.0 111.435 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -106.6 98.08 19.2 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.6 0.238 . . . . 0.0 110.888 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -48.04 112.2 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.515 2.144 . . . . 0.0 112.673 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -134.5 -43.99 0.76 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.872 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.547 HG12 ' O ' ' A' ' 9' ' ' VAL . 49.1 t -155.55 56.8 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.923 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 145.2 -104.9 0.33 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.564 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -104.4 -31.28 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.329 . . . . 0.0 110.976 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 164.9 162.68 16.46 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.545 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 11.1 ttp-105 . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.863 0.363 . . . . 0.0 111.059 -179.884 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.203 0 N-CA-C 112.587 -0.205 . . . . 0.0 112.587 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -75.21 -92.27 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.517 2.145 . . . . 0.0 112.449 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.41 86.79 6.55 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-O 120.689 0.28 . . . . 0.0 111.164 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.49 -155.13 6.32 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.567 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -112.83 -22.38 10.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.679 0.276 . . . . 0.0 111.267 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.415 ' CD2' ' N ' ' A' ' 6' ' ' PHE . 4.9 m-85 -112.36 98.67 44.24 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.909 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_exo -47.55 116.06 1.67 Allowed 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.631 2.221 . . . . 0.0 112.647 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.686 ' OD1' HG12 ' A' ' 9' ' ' VAL . 2.6 p-10 -127.05 -45.0 1.58 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.82 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.686 HG12 ' OD1' ' A' ' 8' ' ' ASP . 14.5 p -157.81 50.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.068 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.19 -98.86 0.17 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.392 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -124.35 5.12 8.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.567 0.222 . . . . 0.0 111.302 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.67 153.57 7.88 Favored Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.749 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.6 ptm180 . . . . . 0 C--N 1.33 -0.26 0 CA-C-O 120.806 0.336 . . . . 0.0 110.79 179.786 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . 0.41 ' HA3' ' HB3' ' A' ' 13' ' ' ARG . . . . . . . . 0 N--CA 1.452 -0.274 0 N-CA-C 112.703 -0.159 . . . . 0.0 112.703 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -80.07 -92.6 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.438 0 C-N-CA 122.624 2.216 . . . . 0.0 112.438 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.43 91.37 8.43 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.743 0.306 . . . . 0.0 111.083 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.84 -152.75 5.7 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.538 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -112.27 -24.45 9.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.682 0.277 . . . . 0.0 111.204 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -110.66 91.0 11.43 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.776 -179.783 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.446 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 85.4 Cg_exo -44.47 96.28 0.03 OUTLIER 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.743 2.296 . . . . 0.0 112.642 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.679 ' OD1' HG12 ' A' ' 9' ' ' VAL . 1.7 p30 -96.83 -46.07 6.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.679 HG12 ' OD1' ' A' ' 8' ' ' ASP . 14.7 p -146.41 41.25 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.039 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.01 -90.68 0.11 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.516 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -108.26 -31.46 7.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.815 0.34 . . . . 0.0 110.891 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.446 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 145.01 170.35 14.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.741 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ARG . . . . . 0.41 ' HB3' ' HA3' ' A' ' 1' ' ' GLY . 1.1 ptm180 . . . . . 0 C--N 1.33 -0.272 0 CA-C-O 120.83 0.348 . . . . 0.0 110.924 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.783 -0.127 . . . . 0.0 112.783 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -79.59 -91.08 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.451 0 C-N-CA 122.562 2.175 . . . . 0.0 112.592 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.43 90.17 7.91 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.679 0.276 . . . . 0.0 111.237 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.81 -155.36 6.5 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.42 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ASP . . . . . 0.405 ' OD2' ' CE2' ' A' ' 6' ' ' PHE . 1.4 p30 -112.37 -23.26 10.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.785 0.326 . . . . 0.0 111.12 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.405 ' CE2' ' OD2' ' A' ' 5' ' ' ASP . 17.9 m-85 -108.45 96.0 17.77 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.035 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -47.83 110.06 0.28 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.519 2.146 . . . . 0.0 112.44 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.798 ' OD1' HG12 ' A' ' 9' ' ' VAL . 1.5 p30 -115.51 -43.9 3.01 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.999 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.798 HG12 ' OD1' ' A' ' 8' ' ' ASP . 12.7 p -157.84 34.77 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.059 179.804 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 178.05 -100.59 0.14 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.504 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -111.11 -28.71 8.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.714 0.293 . . . . 0.0 111.05 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.04 163.68 22.4 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.862 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.255 0 CA-C-O 120.841 0.353 . . . . 0.0 110.931 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . 0.542 ' HA2' HG12 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.453 -0.209 0 N-CA-C 112.652 -0.179 . . . . 0.0 112.652 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.42 -93.63 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.447 0 C-N-CA 122.58 2.187 . . . . 0.0 112.228 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.61 91.13 8.29 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.775 0.322 . . . . 0.0 111.098 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.07 -159.09 8.38 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.471 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.47 -20.92 12.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.649 0.261 . . . . 0.0 111.189 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -111.31 92.76 16.7 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.726 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PRO . . . . . 0.409 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 80.5 Cg_exo -45.39 127.82 9.6 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.694 2.263 . . . . 0.0 112.665 -179.789 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.433 ' OD1' HG12 ' A' ' 9' ' ' VAL . 3.0 p-10 -139.81 -46.05 0.44 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.938 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.605 ' O ' HG22 ' A' ' 9' ' ' VAL . 14.8 p -147.55 38.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.971 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 162.08 -90.15 0.11 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.491 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.54 -39.19 3.37 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.857 0.36 . . . . 0.0 110.778 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 171.53 160.77 20.85 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.592 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.26 0 CA-C-O 120.871 0.367 . . . . 0.0 110.948 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 CA-C-O 120.351 -0.138 . . . . 0.0 112.781 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -75.58 -90.66 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.42 0 C-N-CA 122.566 2.178 . . . . 0.0 112.504 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -90.38 86.74 6.55 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.738 0.304 . . . . 0.0 111.179 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.05 -158.87 8.27 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.54 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -112.02 -17.11 12.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.566 0.222 . . . . 0.0 111.343 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -108.69 92.67 10.67 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.896 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_exo -46.4 116.45 1.56 Allowed 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.547 2.165 . . . . 0.0 112.63 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ASP . . . . . 0.743 ' OD1' HG12 ' A' ' 9' ' ' VAL . 2.3 p-10 -131.95 -45.58 0.95 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.927 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.743 HG12 ' OD1' ' A' ' 8' ' ' ASP . 12.1 p -154.65 46.21 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.985 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 161.81 -103.12 0.22 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.323 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -110.06 -25.97 9.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.725 0.298 . . . . 0.0 110.907 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.56 162.7 12.4 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.691 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.28 0 CA-C-O 120.749 0.309 . . . . 0.0 110.811 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.255 0 N-CA-C 112.758 -0.137 . . . . 0.0 112.758 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' PRO . . . . . 0.428 ' O ' ' N ' ' A' ' 12' ' ' GLY . 60.2 Cg_endo -75.67 -91.07 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.595 2.197 . . . . 0.0 112.565 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 ttpt -90.52 86.73 6.5 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.621 0.248 . . . . 0.0 111.15 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -137.23 -97.56 0.46 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.625 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -171.32 -37.77 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.892 0.377 . . . . 0.0 110.715 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -105.65 97.46 14.68 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.435 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -40.92 111.18 0.14 Allowed 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 122.902 2.402 . . . . 0.0 112.957 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -116.08 -47.17 2.78 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.859 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' VAL . . . . . 0.609 HG12 ' O ' ' A' ' 9' ' ' VAL . 29.2 t -155.61 41.9 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.859 179.796 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.83 -81.73 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.531 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -128.95 -45.48 1.27 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.808 0.337 . . . . 0.0 110.928 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 2' ' ' PRO . . . -176.79 154.03 15.29 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.687 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 111.041 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.229 0 N-CA-C 112.706 -0.158 . . . . 0.0 112.706 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -85.07 -84.5 0.0 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.765 2.31 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.34 94.79 9.89 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.772 0.32 . . . . 0.0 110.923 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -161.45 -168.37 23.24 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.682 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.34 -7.04 17.9 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.613 0.244 . . . . 0.0 111.436 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -109.74 89.85 8.27 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-N 116.607 -0.269 . . . . 0.0 110.765 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_exo -43.07 121.68 2.46 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.799 2.333 . . . . 0.0 112.749 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -138.68 -57.42 0.63 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.113 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 9' ' ' VAL . 12.5 t -144.75 32.31 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.163 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.89 -102.37 0.18 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.512 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -98.45 -35.2 10.35 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.81 0.338 . . . . 0.0 110.763 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.31 172.62 26.69 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.667 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 20.9 ttp180 -116.93 165.54 13.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.815 0.341 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 29.3 pt -115.85 -37.32 2.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.112 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 63.5 tp -122.8 143.53 49.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.8 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.28 51.26 1.68 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.136 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.379 -1.234 . . . . 0.0 112.464 179.948 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.582 -0.207 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -72.74 -90.2 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.384 0 C-N-CA 122.406 2.07 . . . . 0.0 112.326 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.49 84.71 5.99 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.655 0.264 . . . . 0.0 111.033 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.858 ' HA2' HG23 ' A' ' 14' ' ' ILE . . . -152.26 -163.63 11.72 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.698 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -109.2 -7.83 15.22 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.582 0.23 . . . . 0.0 111.485 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -111.0 84.45 4.39 Favored Pre-proline 0 C--N 1.331 -0.206 0 CA-C-O 120.711 0.291 . . . . 0.0 110.748 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -43.42 110.59 0.19 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.811 2.341 . . . . 0.0 112.909 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -132.55 -46.48 0.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.789 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.569 HG12 ' O ' ' A' ' 9' ' ' VAL . 44.8 t -148.58 54.01 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.936 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 146.63 -103.3 0.27 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.416 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -102.6 -33.25 9.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.873 0.368 . . . . 0.0 110.644 179.773 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.41 166.69 15.92 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.624 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 9.9 ttm180 -98.41 141.67 30.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.814 0.34 . . . . 0.0 111.052 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.858 HG23 ' HA2' ' A' ' 4' ' ' GLY . 1.4 pp -113.59 -27.46 2.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.155 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.725 ' N ' HD12 ' A' ' 14' ' ' ILE . 1.0 OUTLIER -128.95 81.7 2.04 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.754 179.935 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -94.77 46.08 1.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.132 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.029 0 CA-C-O 118.356 -1.246 . . . . 0.0 112.499 -179.975 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.589 ' HA2' HG12 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.452 -0.255 0 N-CA-C 112.679 -0.168 . . . . 0.0 112.679 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -73.48 -90.92 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 122.497 2.131 . . . . 0.0 112.433 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.39 85.33 6.15 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 120.775 0.322 . . . . 0.0 111.175 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.41 -159.29 8.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.55 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 13.8 p30 -111.59 -19.25 12.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.657 0.265 . . . . 0.0 111.325 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -109.4 92.78 12.21 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.784 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.4 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 88.7 Cg_exo -44.18 137.14 7.66 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.797 2.331 . . . . 0.0 112.723 -179.726 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -157.75 -44.01 0.06 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.954 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.593 ' O ' HG22 ' A' ' 9' ' ' VAL . 14.6 p -149.46 41.41 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.05 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.53 -95.75 0.15 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.395 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -112.64 -37.1 5.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.807 0.337 . . . . 0.0 110.711 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 169.39 159.06 14.2 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.652 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 42.5 ptt85 -107.48 -172.87 2.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.872 0.367 . . . . 0.0 110.976 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 9.2 pt -138.82 -42.94 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.258 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.429 HD13 ' HA ' ' A' ' 15' ' ' LEU . 3.9 mm? -92.4 151.9 20.0 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.881 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -104.86 -32.27 8.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.09 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.402 -1.221 . . . . 0.0 112.523 179.986 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.272 0 CA-C-O 120.368 -0.129 . . . . 0.0 112.844 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -74.75 -88.04 0.0 OUTLIER 'Trans proline' 0 CA--C 1.531 0.365 0 C-N-CA 122.578 2.186 . . . . 0.0 112.527 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.16 85.42 6.26 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.836 0.35 . . . . 0.0 111.062 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.448 ' HA2' HG23 ' A' ' 14' ' ' ILE . . . -152.84 -175.93 24.85 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.644 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.403 ' O ' ' CD1' ' A' ' 6' ' ' PHE . 15.3 m-20 -107.0 29.28 7.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.845 0.355 . . . . 0.0 110.991 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.403 ' CD1' ' O ' ' A' ' 5' ' ' ASP . 6.6 m-85 -149.72 87.87 5.03 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.619 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_exo -43.81 106.46 0.08 OUTLIER 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.701 2.267 . . . . 0.0 112.712 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -126.82 -45.17 1.61 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.9 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.504 HG12 ' O ' ' A' ' 9' ' ' VAL . 44.6 t -155.5 59.35 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.906 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.58 -99.19 0.21 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.384 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -108.93 -31.96 7.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.741 0.305 . . . . 0.0 110.749 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.32 164.4 13.35 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.735 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 4.7 ttp85 -115.95 173.12 6.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.327 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.665 ' N ' HD13 ' A' ' 14' ' ' ILE . 0.2 OUTLIER -143.43 28.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.181 179.955 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.418 HD13 ' HA ' ' A' ' 15' ' ' LEU . 1.2 mm? -127.26 163.82 23.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.818 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.3 -67.39 0.45 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.112 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.114 0 CA-C-O 118.41 -1.217 . . . . 0.0 112.515 -179.951 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 N-CA-C 112.622 -0.191 . . . . 0.0 112.622 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -72.71 -90.38 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.408 0 C-N-CA 122.414 2.076 . . . . 0.0 112.288 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 4.9 ttpt -90.21 84.66 6.11 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.729 0.3 . . . . 0.0 111.027 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.01 -158.43 7.82 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.635 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -114.06 -16.71 12.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.554 0.216 . . . . 0.0 111.345 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -109.33 91.13 9.28 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 120.679 0.276 . . . . 0.0 110.806 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.434 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 93.7 Cg_exo -43.23 114.52 0.47 Allowed 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.843 2.362 . . . . 0.0 112.846 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.457 ' OD1' HG23 ' A' ' 9' ' ' VAL . 3.3 p-10 -134.33 -44.84 0.77 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.576 HG12 ' O ' ' A' ' 9' ' ' VAL . 50.0 t -145.15 54.82 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.777 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 137.68 -92.62 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.317 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -105.56 -40.99 5.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.814 0.34 . . . . 0.0 110.695 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.434 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 156.76 167.6 18.2 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.686 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 7.7 ptt-85 -106.8 154.58 20.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.755 0.312 . . . . 0.0 110.766 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 7.9 tp -93.4 -30.9 4.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.193 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.4 mt -108.48 141.15 40.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.927 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.93 81.93 1.38 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.096 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.031 0 CA-C-O 118.369 -1.24 . . . . 0.0 112.493 -180.0 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.586 -0.205 . . . . 0.0 112.586 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -88.34 -77.72 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.872 2.381 . . . . 0.0 112.422 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -90.14 96.11 10.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.785 0.326 . . . . 0.0 111.049 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.566 ' HA2' HD12 ' A' ' 14' ' ' ILE . . . -170.06 -161.81 21.22 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.515 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -125.93 27.6 6.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.798 0.332 . . . . 0.0 111.076 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.07 93.53 4.73 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.631 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_exo -43.18 121.43 2.42 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.73 2.287 . . . . 0.0 112.86 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -143.17 -45.81 0.3 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.82 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.65 HG12 ' O ' ' A' ' 9' ' ' VAL . 44.4 t -156.13 38.57 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.077 0.465 . . . . 0.0 110.619 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 163.79 -107.97 0.32 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.364 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -101.5 -30.89 11.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.776 0.322 . . . . 0.0 110.824 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.7 165.67 15.18 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.811 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 12.9 ptt180 -126.57 160.17 31.4 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.727 0.298 . . . . 0.0 110.993 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.638 ' N ' HD13 ' A' ' 14' ' ' ILE . 0.2 OUTLIER -155.51 25.72 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.301 179.803 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.4 mt -141.59 57.24 1.51 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.977 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.87 68.9 7.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.134 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.341 -1.255 . . . . 0.0 112.515 179.934 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 0.188 0 N-CA-C 112.626 -0.189 . . . . 0.0 112.626 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -74.73 -93.03 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.454 2.103 . . . . 0.0 112.522 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 ttpt -90.23 86.47 6.53 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.774 0.321 . . . . 0.0 111.159 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.0 -145.68 4.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.467 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -118.95 -25.4 6.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.583 0.23 . . . . 0.0 111.573 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -119.1 106.0 43.95 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.048 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.483 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 87.4 Cg_exo -46.44 112.95 0.53 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.639 2.226 . . . . 0.0 112.677 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -118.52 -45.35 2.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.855 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.584 HG12 ' O ' ' A' ' 9' ' ' VAL . 48.7 t -155.46 54.53 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.766 179.706 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.93 -84.35 0.16 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.345 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -121.39 -40.03 2.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.712 0.292 . . . . 0.0 110.776 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.483 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 160.79 167.08 20.77 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.865 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.3 ptt180 -127.36 152.71 47.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.758 0.313 . . . . 0.0 110.9 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.542 HD12 ' HG ' ' A' ' 15' ' ' LEU . 1.9 pp -128.25 25.96 2.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.254 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.561 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.5 OUTLIER -150.06 89.62 1.61 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.872 -179.995 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -127.32 -76.13 0.57 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.096 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.424 -1.209 . . . . 0.0 112.534 -179.959 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.358 -0.297 . . . . 0.0 112.358 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.75 -94.35 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.391 0 C-N-CA 122.344 2.029 . . . . 0.0 112.174 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.439 ' O ' HG23 ' A' ' 14' ' ' ILE . 11.1 ttmm -90.53 86.14 6.33 Favored 'General case' 0 C--N 1.333 -0.111 0 CA-C-O 120.714 0.292 . . . . 0.0 111.09 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.11 -155.89 6.63 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.609 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -111.75 -21.82 11.46 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.599 0.238 . . . . 0.0 111.352 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -108.99 92.96 11.62 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.908 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.458 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 80.2 Cg_exo -45.39 119.18 2.47 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.744 2.296 . . . . 0.0 112.793 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.765 ' OD1' HG23 ' A' ' 9' ' ' VAL . 4.1 p-10 -135.83 -47.27 0.67 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.713 179.703 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.765 HG23 ' OD1' ' A' ' 8' ' ' ASP . 24.9 t -136.81 31.64 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.691 179.697 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.56 -102.28 0.21 Allowed Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.346 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.88 -33.53 11.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.776 0.322 . . . . 0.0 110.604 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.458 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 157.09 164.47 13.66 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.779 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.23 135.25 46.95 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.748 0.308 . . . . 0.0 110.764 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 3' ' ' LYS . 19.7 pt -86.4 -33.26 7.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.25 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.421 ' HA ' HD22 ' A' ' 15' ' ' LEU . 0.6 OUTLIER -103.57 114.71 29.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.923 -179.931 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -114.35 74.22 0.86 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.013 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.383 -1.231 . . . . 0.0 112.517 -179.969 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.602 -0.199 . . . . 0.0 112.602 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -74.16 -92.98 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.435 0 C-N-CA 122.494 2.129 . . . . 0.0 112.351 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -90.42 86.53 6.48 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.799 0.333 . . . . 0.0 111.006 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.2 -154.49 6.23 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.619 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -116.44 -18.2 10.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.579 0.228 . . . . 0.0 111.435 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -106.6 98.08 19.2 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.6 0.238 . . . . 0.0 110.888 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -48.04 112.2 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.515 2.144 . . . . 0.0 112.673 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -134.5 -43.99 0.76 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.872 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.547 HG12 ' O ' ' A' ' 9' ' ' VAL . 49.1 t -155.55 56.8 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.923 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 145.2 -104.9 0.33 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.564 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -104.4 -31.28 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.329 . . . . 0.0 110.976 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 164.9 162.68 16.46 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.545 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 11.1 ttp-105 -106.28 165.95 10.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.863 0.363 . . . . 0.0 111.059 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 2.7 pt -145.08 32.78 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.988 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 13.7 mt -133.1 95.28 3.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.85 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -136.18 116.74 13.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.336 -1.258 . . . . 0.0 112.497 179.979 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.203 0 N-CA-C 112.587 -0.205 . . . . 0.0 112.587 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -75.21 -92.27 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.517 2.145 . . . . 0.0 112.449 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.618 ' O ' HD11 ' A' ' 14' ' ' ILE . 0.0 OUTLIER -90.41 86.79 6.55 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-O 120.689 0.28 . . . . 0.0 111.164 -179.936 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.49 -155.13 6.32 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.567 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -112.83 -22.38 10.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.679 0.276 . . . . 0.0 111.267 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.415 ' CD2' ' N ' ' A' ' 6' ' ' PHE . 4.9 m-85 -112.36 98.67 44.24 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.909 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_exo -47.55 116.06 1.67 Allowed 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.631 2.221 . . . . 0.0 112.647 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.686 ' OD1' HG12 ' A' ' 9' ' ' VAL . 2.6 p-10 -127.05 -45.0 1.58 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.82 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.686 HG12 ' OD1' ' A' ' 8' ' ' ASP . 14.5 p -157.81 50.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.068 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.19 -98.86 0.17 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.392 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -124.35 5.12 8.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.567 0.222 . . . . 0.0 111.302 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.67 153.57 7.88 Favored Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.749 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.6 ptm180 -105.46 152.8 22.56 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.806 0.336 . . . . 0.0 110.79 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.618 HD11 ' O ' ' A' ' 3' ' ' LYS . 1.1 mp -111.65 -28.99 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.175 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.62 HD22 ' N ' ' A' ' 15' ' ' LEU . 0.1 OUTLIER -107.56 154.43 21.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.829 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -112.11 70.88 0.72 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.085 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.087 0 CA-C-O 118.341 -1.255 . . . . 0.0 112.474 -179.97 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.41 ' HA3' ' HB3' ' A' ' 13' ' ' ARG . . . . . . . . 0 N--CA 1.452 -0.274 0 N-CA-C 112.703 -0.159 . . . . 0.0 112.703 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -80.07 -92.6 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.438 0 C-N-CA 122.624 2.216 . . . . 0.0 112.438 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.43 91.37 8.43 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.743 0.306 . . . . 0.0 111.083 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.84 -152.75 5.7 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.538 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -112.27 -24.45 9.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.682 0.277 . . . . 0.0 111.204 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -110.66 91.0 11.43 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.776 -179.783 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.446 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 85.4 Cg_exo -44.47 96.28 0.03 OUTLIER 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.743 2.296 . . . . 0.0 112.642 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.679 ' OD1' HG12 ' A' ' 9' ' ' VAL . 1.7 p30 -96.83 -46.07 6.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.679 HG12 ' OD1' ' A' ' 8' ' ' ASP . 14.7 p -146.41 41.25 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.039 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.01 -90.68 0.11 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.516 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -108.26 -31.46 7.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.815 0.34 . . . . 0.0 110.891 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.446 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 145.01 170.35 14.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.741 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ARG . . . . . 0.808 ' NH2' HD23 ' A' ' 15' ' ' LEU . 1.1 ptm180 -115.88 165.68 12.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.83 0.348 . . . . 0.0 110.924 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.405 ' C ' HD12 ' A' ' 14' ' ' ILE . 1.7 pp -114.92 36.37 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.093 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.808 HD23 ' NH2' ' A' ' 13' ' ' ARG . 33.6 tp -108.19 112.12 24.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.933 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -90.53 52.17 2.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.102 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.355 -1.247 . . . . 0.0 112.517 179.972 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.783 -0.127 . . . . 0.0 112.783 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -79.59 -91.08 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.451 0 C-N-CA 122.562 2.175 . . . . 0.0 112.592 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.43 90.17 7.91 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.679 0.276 . . . . 0.0 111.237 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.81 -155.36 6.5 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.42 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ASP . . . . . 0.405 ' OD2' ' CE2' ' A' ' 6' ' ' PHE . 1.4 p30 -112.37 -23.26 10.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.785 0.326 . . . . 0.0 111.12 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.405 ' CE2' ' OD2' ' A' ' 5' ' ' ASP . 17.9 m-85 -108.45 96.0 17.77 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.035 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -47.83 110.06 0.28 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.519 2.146 . . . . 0.0 112.44 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.798 ' OD1' HG12 ' A' ' 9' ' ' VAL . 1.5 p30 -115.51 -43.9 3.01 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.999 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.798 HG12 ' OD1' ' A' ' 8' ' ' ASP . 12.7 p -157.84 34.77 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.059 179.804 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 178.05 -100.59 0.14 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.504 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -111.11 -28.71 8.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.714 0.293 . . . . 0.0 111.05 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.04 163.68 22.4 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.862 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.36 175.04 5.6 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.841 0.353 . . . . 0.0 110.931 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 30.2 mm -114.12 -38.85 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.024 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -122.92 105.58 10.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.899 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -135.1 111.47 9.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.059 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.38 -1.233 . . . . 0.0 112.551 179.984 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . 0.542 ' HA2' HG12 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.453 -0.209 0 N-CA-C 112.652 -0.179 . . . . 0.0 112.652 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.42 -93.63 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.447 0 C-N-CA 122.58 2.187 . . . . 0.0 112.228 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.61 91.13 8.29 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.775 0.322 . . . . 0.0 111.098 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.07 -159.09 8.38 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.471 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.47 -20.92 12.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.649 0.261 . . . . 0.0 111.189 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -111.31 92.76 16.7 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.726 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . 0.409 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 80.5 Cg_exo -45.39 127.82 9.6 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.694 2.263 . . . . 0.0 112.665 -179.789 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.433 ' OD1' HG12 ' A' ' 9' ' ' VAL . 3.0 p-10 -139.81 -46.05 0.44 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.938 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.605 ' O ' HG22 ' A' ' 9' ' ' VAL . 14.8 p -147.55 38.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.971 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 162.08 -90.15 0.11 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.491 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.54 -39.19 3.37 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.857 0.36 . . . . 0.0 110.778 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 171.53 160.77 20.85 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.592 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.93 -179.07 3.59 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.871 0.367 . . . . 0.0 110.948 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.445 ' C ' HD12 ' A' ' 14' ' ' ILE . 2.2 pp -143.89 27.34 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.126 179.848 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.57 HD23 ' H ' ' A' ' 15' ' ' LEU . 1.3 pt? -150.03 121.68 8.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.942 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -150.06 -170.27 3.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.11 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.081 0 CA-C-O 118.374 -1.237 . . . . 0.0 112.503 -179.979 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 CA-C-O 120.351 -0.138 . . . . 0.0 112.781 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -75.58 -90.66 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.42 0 C-N-CA 122.566 2.178 . . . . 0.0 112.504 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -90.38 86.74 6.55 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.738 0.304 . . . . 0.0 111.179 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.05 -158.87 8.27 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.54 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -112.02 -17.11 12.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.566 0.222 . . . . 0.0 111.343 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -108.69 92.67 10.67 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.896 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_exo -46.4 116.45 1.56 Allowed 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.547 2.165 . . . . 0.0 112.63 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASP . . . . . 0.743 ' OD1' HG12 ' A' ' 9' ' ' VAL . 2.3 p-10 -131.95 -45.58 0.95 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.927 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.743 HG12 ' OD1' ' A' ' 8' ' ' ASP . 12.1 p -154.65 46.21 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.985 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 161.81 -103.12 0.22 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.323 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -110.06 -25.97 9.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.725 0.298 . . . . 0.0 110.907 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.56 162.7 12.4 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.691 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.77 171.17 7.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.749 0.309 . . . . 0.0 110.811 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.498 HG23 ' N ' ' A' ' 15' ' ' LEU . 7.5 tp -146.43 -45.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.09 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.498 ' N ' HG23 ' A' ' 14' ' ' ILE . 0.9 OUTLIER -114.83 121.21 42.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.765 -179.951 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -107.53 30.79 5.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.196 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.382 -1.232 . . . . 0.0 112.522 179.943 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.255 0 N-CA-C 112.758 -0.137 . . . . 0.0 112.758 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' PRO . . . . . 0.428 ' O ' ' N ' ' A' ' 12' ' ' GLY . 60.2 Cg_endo -75.67 -91.07 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.595 2.197 . . . . 0.0 112.565 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.461 ' O ' HD11 ' A' ' 14' ' ' ILE . 1.1 ttpt -90.52 86.73 6.5 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.621 0.248 . . . . 0.0 111.15 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -137.23 -97.56 0.46 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.625 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -171.32 -37.77 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.892 0.377 . . . . 0.0 110.715 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -105.65 97.46 14.68 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.435 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -40.92 111.18 0.14 Allowed 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 122.902 2.402 . . . . 0.0 112.957 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -116.08 -47.17 2.78 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.859 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' VAL . . . . . 0.609 HG12 ' O ' ' A' ' 9' ' ' VAL . 29.2 t -155.61 41.9 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.859 179.796 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.83 -81.73 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.531 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -128.95 -45.48 1.27 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.808 0.337 . . . . 0.0 110.928 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 2' ' ' PRO . . . -176.79 154.03 15.29 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.687 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.41 174.44 5.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 111.041 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.572 ' O ' HG22 ' A' ' 14' ' ' ILE . 18.3 mt -132.6 32.34 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.063 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.0 mt -131.99 156.55 46.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -137.33 152.19 49.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.373 -1.237 . . . . 0.0 112.514 179.975 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.229 0 N-CA-C 112.706 -0.158 . . . . 0.0 112.706 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -85.07 -84.5 0.0 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.765 2.31 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.34 94.79 9.89 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.772 0.32 . . . . 0.0 110.923 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -161.45 -168.37 23.24 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.682 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.34 -7.04 17.9 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.613 0.244 . . . . 0.0 111.436 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -109.74 89.85 8.27 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-N 116.607 -0.269 . . . . 0.0 110.765 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_exo -43.07 121.68 2.46 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.799 2.333 . . . . 0.0 112.749 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -138.68 -57.42 0.63 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.113 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.545 ' O ' HG12 ' A' ' 9' ' ' VAL . 12.5 t -144.75 32.31 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.163 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.89 -102.37 0.18 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.512 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -98.45 -35.2 10.35 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.81 0.338 . . . . 0.0 110.763 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.31 172.62 26.69 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.667 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 20.9 ttp180 . . . . . 0 C--N 1.33 -0.28 0 CA-C-O 120.815 0.341 . . . . 0.0 110.841 -179.938 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.582 -0.207 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -72.74 -90.2 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.384 0 C-N-CA 122.406 2.07 . . . . 0.0 112.326 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.49 84.71 5.99 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.655 0.264 . . . . 0.0 111.033 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -152.26 -163.63 11.72 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.698 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -109.2 -7.83 15.22 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.582 0.23 . . . . 0.0 111.485 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -111.0 84.45 4.39 Favored Pre-proline 0 C--N 1.331 -0.206 0 CA-C-O 120.711 0.291 . . . . 0.0 110.748 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -43.42 110.59 0.19 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.811 2.341 . . . . 0.0 112.909 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -132.55 -46.48 0.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.789 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.569 ' O ' HG12 ' A' ' 9' ' ' VAL . 44.8 t -148.58 54.01 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.936 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 146.63 -103.3 0.27 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.416 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -102.6 -33.25 9.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.873 0.368 . . . . 0.0 110.644 179.773 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.41 166.69 15.92 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.624 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 9.9 ttm180 . . . . . 0 C--N 1.329 -0.325 0 CA-C-O 120.814 0.34 . . . . 0.0 111.052 -179.895 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . 0.589 ' HA2' HG12 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.452 -0.255 0 N-CA-C 112.679 -0.168 . . . . 0.0 112.679 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -73.48 -90.92 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 122.497 2.131 . . . . 0.0 112.433 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.39 85.33 6.15 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 120.775 0.322 . . . . 0.0 111.175 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.41 -159.29 8.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.55 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 13.8 p30 -111.59 -19.25 12.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.657 0.265 . . . . 0.0 111.325 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -109.4 92.78 12.21 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.784 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.4 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 88.7 Cg_exo -44.18 137.14 7.66 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.797 2.331 . . . . 0.0 112.723 -179.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -157.75 -44.01 0.06 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.954 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.593 ' O ' HG22 ' A' ' 9' ' ' VAL . 14.6 p -149.46 41.41 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.05 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.53 -95.75 0.15 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.395 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -112.64 -37.1 5.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.807 0.337 . . . . 0.0 110.711 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 169.39 159.06 14.2 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.652 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 42.5 ptt85 . . . . . 0 C--N 1.33 -0.27 0 CA-C-O 120.872 0.367 . . . . 0.0 110.976 179.92 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.272 0 CA-C-O 120.368 -0.129 . . . . 0.0 112.844 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -74.75 -88.04 0.0 OUTLIER 'Trans proline' 0 CA--C 1.531 0.365 0 C-N-CA 122.578 2.186 . . . . 0.0 112.527 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.16 85.42 6.26 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.836 0.35 . . . . 0.0 111.062 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -152.84 -175.93 24.85 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.644 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.403 ' O ' ' CD1' ' A' ' 6' ' ' PHE . 15.3 m-20 -107.0 29.28 7.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.845 0.355 . . . . 0.0 110.991 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.403 ' CD1' ' O ' ' A' ' 5' ' ' ASP . 6.6 m-85 -149.72 87.87 5.03 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.619 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_exo -43.81 106.46 0.08 OUTLIER 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.701 2.267 . . . . 0.0 112.712 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -126.82 -45.17 1.61 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.9 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.504 ' O ' HG12 ' A' ' 9' ' ' VAL . 44.6 t -155.5 59.35 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.906 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.58 -99.19 0.21 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.384 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -108.93 -31.96 7.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.741 0.305 . . . . 0.0 110.749 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.32 164.4 13.35 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.735 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 4.7 ttp85 . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.327 . . . . 0.0 110.875 -179.997 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 N-CA-C 112.622 -0.191 . . . . 0.0 112.622 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -72.71 -90.38 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.408 0 C-N-CA 122.414 2.076 . . . . 0.0 112.288 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 4.9 ttpt -90.21 84.66 6.11 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.729 0.3 . . . . 0.0 111.027 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.01 -158.43 7.82 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.635 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -114.06 -16.71 12.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.554 0.216 . . . . 0.0 111.345 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -109.33 91.13 9.28 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 120.679 0.276 . . . . 0.0 110.806 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.434 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 93.7 Cg_exo -43.23 114.52 0.47 Allowed 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.843 2.362 . . . . 0.0 112.846 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.457 ' OD1' HG23 ' A' ' 9' ' ' VAL . 3.3 p-10 -134.33 -44.84 0.77 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.576 ' O ' HG12 ' A' ' 9' ' ' VAL . 50.0 t -145.15 54.82 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.777 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 137.68 -92.62 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.317 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -105.56 -40.99 5.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.814 0.34 . . . . 0.0 110.695 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.434 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 156.76 167.6 18.2 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.686 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 7.7 ptt-85 . . . . . 0 C--N 1.33 -0.245 0 CA-C-O 120.755 0.312 . . . . 0.0 110.766 179.945 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.586 -0.205 . . . . 0.0 112.586 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -88.34 -77.72 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.872 2.381 . . . . 0.0 112.422 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -90.14 96.11 10.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.785 0.326 . . . . 0.0 111.049 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -170.06 -161.81 21.22 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.515 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -125.93 27.6 6.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.798 0.332 . . . . 0.0 111.076 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.07 93.53 4.73 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.631 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_exo -43.18 121.43 2.42 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.73 2.287 . . . . 0.0 112.86 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -143.17 -45.81 0.3 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.82 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.65 ' O ' HG12 ' A' ' 9' ' ' VAL . 44.4 t -156.13 38.57 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.077 0.465 . . . . 0.0 110.619 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 163.79 -107.97 0.32 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.364 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -101.5 -30.89 11.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.776 0.322 . . . . 0.0 110.824 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.7 165.67 15.18 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.811 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 12.9 ptt180 . . . . . 0 C--N 1.33 -0.274 0 CA-C-O 120.727 0.298 . . . . 0.0 110.993 179.957 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 0.188 0 N-CA-C 112.626 -0.189 . . . . 0.0 112.626 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -74.73 -93.03 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.454 2.103 . . . . 0.0 112.522 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 ttpt -90.23 86.47 6.53 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.774 0.321 . . . . 0.0 111.159 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.0 -145.68 4.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.467 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -118.95 -25.4 6.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.583 0.23 . . . . 0.0 111.573 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -119.1 106.0 43.95 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.048 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.483 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 87.4 Cg_exo -46.44 112.95 0.53 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.639 2.226 . . . . 0.0 112.677 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -118.52 -45.35 2.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.855 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.584 ' O ' HG12 ' A' ' 9' ' ' VAL . 48.7 t -155.46 54.53 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.766 179.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.93 -84.35 0.16 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.345 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -121.39 -40.03 2.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.712 0.292 . . . . 0.0 110.776 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.483 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 160.79 167.08 20.77 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.865 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.3 ptt180 . . . . . 0 C--N 1.33 -0.242 0 CA-C-O 120.758 0.313 . . . . 0.0 110.9 179.882 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.358 -0.297 . . . . 0.0 112.358 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.75 -94.35 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.391 0 C-N-CA 122.344 2.029 . . . . 0.0 112.174 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 11.1 ttmm -90.53 86.14 6.33 Favored 'General case' 0 C--N 1.333 -0.111 0 CA-C-O 120.714 0.292 . . . . 0.0 111.09 179.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.11 -155.89 6.63 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.609 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -111.75 -21.82 11.46 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.599 0.238 . . . . 0.0 111.352 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -108.99 92.96 11.62 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.908 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.458 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 80.2 Cg_exo -45.39 119.18 2.47 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.744 2.296 . . . . 0.0 112.793 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.765 ' OD1' HG23 ' A' ' 9' ' ' VAL . 4.1 p-10 -135.83 -47.27 0.67 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.713 179.703 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.765 HG23 ' OD1' ' A' ' 8' ' ' ASP . 24.9 t -136.81 31.64 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.691 179.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.56 -102.28 0.21 Allowed Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.346 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.88 -33.53 11.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.776 0.322 . . . . 0.0 110.604 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.458 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 157.09 164.47 13.66 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.779 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.256 0 CA-C-O 120.748 0.308 . . . . 0.0 110.764 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.602 -0.199 . . . . 0.0 112.602 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -74.16 -92.98 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.435 0 C-N-CA 122.494 2.129 . . . . 0.0 112.351 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -90.42 86.53 6.48 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.799 0.333 . . . . 0.0 111.006 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.2 -154.49 6.23 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.619 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -116.44 -18.2 10.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.579 0.228 . . . . 0.0 111.435 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -106.6 98.08 19.2 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.6 0.238 . . . . 0.0 110.888 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -48.04 112.2 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.515 2.144 . . . . 0.0 112.673 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -134.5 -43.99 0.76 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.872 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.547 ' O ' HG12 ' A' ' 9' ' ' VAL . 49.1 t -155.55 56.8 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.923 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 145.2 -104.9 0.33 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.564 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -104.4 -31.28 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.329 . . . . 0.0 110.976 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 164.9 162.68 16.46 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.545 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 11.1 ttp-105 . . . . . 0 C--N 1.329 -0.316 0 CA-C-O 120.863 0.363 . . . . 0.0 111.059 -179.884 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.203 0 N-CA-C 112.587 -0.205 . . . . 0.0 112.587 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -75.21 -92.27 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.517 2.145 . . . . 0.0 112.449 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.41 86.79 6.55 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-O 120.689 0.28 . . . . 0.0 111.164 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.49 -155.13 6.32 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.567 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -112.83 -22.38 10.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.679 0.276 . . . . 0.0 111.267 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.415 ' CD2' ' N ' ' A' ' 6' ' ' PHE . 4.9 m-85 -112.36 98.67 44.24 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.909 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_exo -47.55 116.06 1.67 Allowed 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.631 2.221 . . . . 0.0 112.647 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.686 ' OD1' HG12 ' A' ' 9' ' ' VAL . 2.6 p-10 -127.05 -45.0 1.58 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.82 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.686 HG12 ' OD1' ' A' ' 8' ' ' ASP . 14.5 p -157.81 50.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.068 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.19 -98.86 0.17 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.392 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -124.35 5.12 8.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.567 0.222 . . . . 0.0 111.302 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.67 153.57 7.88 Favored Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.749 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.6 ptm180 . . . . . 0 C--N 1.33 -0.26 0 CA-C-O 120.806 0.336 . . . . 0.0 110.79 179.786 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . 0.41 ' HA3' ' HB3' ' A' ' 13' ' ' ARG . . . . . . . . 0 N--CA 1.452 -0.274 0 N-CA-C 112.703 -0.159 . . . . 0.0 112.703 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -80.07 -92.6 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.438 0 C-N-CA 122.624 2.216 . . . . 0.0 112.438 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.43 91.37 8.43 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.743 0.306 . . . . 0.0 111.083 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.84 -152.75 5.7 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.538 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -112.27 -24.45 9.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.682 0.277 . . . . 0.0 111.204 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -110.66 91.0 11.43 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.776 -179.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.446 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 85.4 Cg_exo -44.47 96.28 0.03 OUTLIER 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.743 2.296 . . . . 0.0 112.642 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.679 ' OD1' HG12 ' A' ' 9' ' ' VAL . 1.7 p30 -96.83 -46.07 6.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.679 HG12 ' OD1' ' A' ' 8' ' ' ASP . 14.7 p -146.41 41.25 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.039 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.01 -90.68 0.11 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.516 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -108.26 -31.46 7.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.815 0.34 . . . . 0.0 110.891 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.446 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 145.01 170.35 14.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.741 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . 0.41 ' HB3' ' HA3' ' A' ' 1' ' ' GLY . 1.1 ptm180 . . . . . 0 C--N 1.33 -0.272 0 CA-C-O 120.83 0.348 . . . . 0.0 110.924 -179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.783 -0.127 . . . . 0.0 112.783 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -79.59 -91.08 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.451 0 C-N-CA 122.562 2.175 . . . . 0.0 112.592 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.43 90.17 7.91 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.679 0.276 . . . . 0.0 111.237 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.81 -155.36 6.5 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.42 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . 0.405 ' OD2' ' CE2' ' A' ' 6' ' ' PHE . 1.4 p30 -112.37 -23.26 10.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.785 0.326 . . . . 0.0 111.12 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.405 ' CE2' ' OD2' ' A' ' 5' ' ' ASP . 17.9 m-85 -108.45 96.0 17.77 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.035 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -47.83 110.06 0.28 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.519 2.146 . . . . 0.0 112.44 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.798 ' OD1' HG12 ' A' ' 9' ' ' VAL . 1.5 p30 -115.51 -43.9 3.01 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.999 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.798 HG12 ' OD1' ' A' ' 8' ' ' ASP . 12.7 p -157.84 34.77 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.059 179.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 178.05 -100.59 0.14 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.504 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -111.11 -28.71 8.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.714 0.293 . . . . 0.0 111.05 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.04 163.68 22.4 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.862 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.255 0 CA-C-O 120.841 0.353 . . . . 0.0 110.931 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . 0.542 ' HA2' HG12 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.453 -0.209 0 N-CA-C 112.652 -0.179 . . . . 0.0 112.652 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.42 -93.63 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.447 0 C-N-CA 122.58 2.187 . . . . 0.0 112.228 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.61 91.13 8.29 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.775 0.322 . . . . 0.0 111.098 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.07 -159.09 8.38 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.471 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.47 -20.92 12.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.649 0.261 . . . . 0.0 111.189 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -111.31 92.76 16.7 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.726 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . 0.409 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 80.5 Cg_exo -45.39 127.82 9.6 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.694 2.263 . . . . 0.0 112.665 -179.789 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.433 ' OD1' HG12 ' A' ' 9' ' ' VAL . 3.0 p-10 -139.81 -46.05 0.44 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.938 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.605 ' O ' HG22 ' A' ' 9' ' ' VAL . 14.8 p -147.55 38.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.971 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 162.08 -90.15 0.11 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.491 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.54 -39.19 3.37 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.857 0.36 . . . . 0.0 110.778 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 171.53 160.77 20.85 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.592 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.26 0 CA-C-O 120.871 0.367 . . . . 0.0 110.948 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 CA-C-O 120.351 -0.138 . . . . 0.0 112.781 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -75.58 -90.66 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.42 0 C-N-CA 122.566 2.178 . . . . 0.0 112.504 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -90.38 86.74 6.55 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.738 0.304 . . . . 0.0 111.179 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.05 -158.87 8.27 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.54 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -112.02 -17.11 12.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.566 0.222 . . . . 0.0 111.343 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -108.69 92.67 10.67 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.896 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_exo -46.4 116.45 1.56 Allowed 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.547 2.165 . . . . 0.0 112.63 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . 0.743 ' OD1' HG12 ' A' ' 9' ' ' VAL . 2.3 p-10 -131.95 -45.58 0.95 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.927 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.743 HG12 ' OD1' ' A' ' 8' ' ' ASP . 12.1 p -154.65 46.21 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.985 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 161.81 -103.12 0.22 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.323 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -110.06 -25.97 9.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.725 0.298 . . . . 0.0 110.907 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.56 162.7 12.4 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.691 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.28 0 CA-C-O 120.749 0.309 . . . . 0.0 110.811 179.845 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.255 0 N-CA-C 112.758 -0.137 . . . . 0.0 112.758 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' PRO . . . . . 0.428 ' O ' ' N ' ' A' ' 12' ' ' GLY . 60.2 Cg_endo -75.67 -91.07 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.595 2.197 . . . . 0.0 112.565 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.1 ttpt -90.52 86.73 6.5 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.621 0.248 . . . . 0.0 111.15 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -137.23 -97.56 0.46 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.625 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -171.32 -37.77 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.892 0.377 . . . . 0.0 110.715 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -105.65 97.46 14.68 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.435 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -40.92 111.18 0.14 Allowed 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 122.902 2.402 . . . . 0.0 112.957 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -116.08 -47.17 2.78 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.859 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' VAL . . . . . 0.609 ' O ' HG12 ' A' ' 9' ' ' VAL . 29.2 t -155.61 41.9 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.859 179.796 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.83 -81.73 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.531 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -128.95 -45.48 1.27 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.808 0.337 . . . . 0.0 110.928 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 2' ' ' PRO . . . -176.79 154.03 15.29 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.687 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 111.041 -179.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.229 0 N-CA-C 112.706 -0.158 . . . . 0.0 112.706 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -85.07 -84.5 0.0 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.707 0 C-N-CA 122.765 2.31 . . . . 0.0 112.439 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.34 94.79 9.89 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.772 0.32 . . . . 0.0 110.923 179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -161.45 -168.37 23.24 Favored Glycine 0 N--CA 1.453 -0.228 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.682 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 6.0 m-20 -106.34 -7.04 17.9 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.613 0.244 . . . . 0.0 111.436 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 5.5 m-85 -109.74 89.85 8.27 Favored Pre-proline 0 C--N 1.331 -0.211 0 CA-C-N 116.607 -0.269 . . . . 0.0 110.765 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_exo -43.07 121.68 2.46 Favored 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 122.799 2.333 . . . . 0.0 112.749 -179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -138.68 -57.42 0.63 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.113 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.545 ' O ' HG12 ' A' ' 9' ' ' VAL . 12.5 t -144.75 32.31 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.375 -0.375 . . . . 0.0 111.163 179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.89 -102.37 0.18 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.512 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -98.45 -35.2 10.35 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.81 0.338 . . . . 0.0 110.763 179.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.31 172.62 26.69 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.667 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 20.9 ttp180 -116.93 165.54 13.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.815 0.341 . . . . 0.0 110.841 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 29.3 pt -115.85 -37.32 2.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.112 179.967 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 63.5 tp -122.8 143.53 49.78 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.8 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -140.28 51.26 1.68 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.136 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.379 -1.234 . . . . 0.0 112.464 179.948 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.582 -0.207 . . . . 0.0 112.582 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -72.74 -90.2 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.384 0 C-N-CA 122.406 2.07 . . . . 0.0 112.326 -179.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.49 84.71 5.99 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.655 0.264 . . . . 0.0 111.033 179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.858 ' HA2' HG23 ' A' ' 14' ' ' ILE . . . -152.26 -163.63 11.72 Favored Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 120.571 -0.823 . . . . 0.0 112.698 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 2.3 p30 -109.2 -7.83 15.22 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.582 0.23 . . . . 0.0 111.485 -179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -111.0 84.45 4.39 Favored Pre-proline 0 C--N 1.331 -0.206 0 CA-C-O 120.711 0.291 . . . . 0.0 110.748 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_exo -43.42 110.59 0.19 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.811 2.341 . . . . 0.0 112.909 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -132.55 -46.48 0.89 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.789 179.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.569 ' O ' HG12 ' A' ' 9' ' ' VAL . 44.8 t -148.58 54.01 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.936 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 146.63 -103.3 0.27 Allowed Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.416 -179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -102.6 -33.25 9.53 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.873 0.368 . . . . 0.0 110.644 179.773 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 155.41 166.69 15.92 Favored Glycine 0 N--CA 1.45 -0.432 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.624 179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 9.9 ttm180 -98.41 141.67 30.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.814 0.34 . . . . 0.0 111.052 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.858 HG23 ' HA2' ' A' ' 4' ' ' GLY . 1.4 pp -113.59 -27.46 2.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.155 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.725 ' N ' HD12 ' A' ' 14' ' ' ILE . 1.0 OUTLIER -128.95 81.7 2.04 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.754 179.935 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -94.77 46.08 1.13 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.132 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.029 0 CA-C-O 118.356 -1.246 . . . . 0.0 112.499 -179.975 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.589 ' HA2' HG12 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.452 -0.255 0 N-CA-C 112.679 -0.168 . . . . 0.0 112.679 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 57.9 Cg_endo -73.48 -90.92 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.39 0 C-N-CA 122.497 2.131 . . . . 0.0 112.433 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.39 85.33 6.15 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 120.775 0.322 . . . . 0.0 111.175 -179.985 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.41 -159.29 8.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.675 -0.774 . . . . 0.0 112.55 179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 13.8 p30 -111.59 -19.25 12.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.657 0.265 . . . . 0.0 111.325 -179.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -109.4 92.78 12.21 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.54 -0.3 . . . . 0.0 110.784 -179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.4 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 88.7 Cg_exo -44.18 137.14 7.66 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.797 2.331 . . . . 0.0 112.723 -179.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 4.6 p-10 -157.75 -44.01 0.06 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.954 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.593 ' O ' HG22 ' A' ' 9' ' ' VAL . 14.6 p -149.46 41.41 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.05 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.53 -95.75 0.15 Allowed Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.816 -0.706 . . . . 0.0 112.395 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.4 t0 -112.64 -37.1 5.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.807 0.337 . . . . 0.0 110.711 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.4 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 169.39 159.06 14.2 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.652 179.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 42.5 ptt85 -107.48 -172.87 2.16 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.872 0.367 . . . . 0.0 110.976 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 9.2 pt -138.82 -42.94 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.258 179.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.429 ' HA ' HD13 ' A' ' 15' ' ' LEU . 3.9 mm? -92.4 151.9 20.0 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.881 179.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -104.86 -32.27 8.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.09 -179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.402 -1.221 . . . . 0.0 112.523 179.986 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.272 0 CA-C-O 120.368 -0.129 . . . . 0.0 112.844 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.4 Cg_endo -74.75 -88.04 0.0 OUTLIER 'Trans proline' 0 CA--C 1.531 0.365 0 C-N-CA 122.578 2.186 . . . . 0.0 112.527 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.16 85.42 6.26 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.836 0.35 . . . . 0.0 111.062 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.448 ' HA2' HG23 ' A' ' 14' ' ' ILE . . . -152.84 -175.93 24.85 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.644 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.403 ' O ' ' CD1' ' A' ' 6' ' ' PHE . 15.3 m-20 -107.0 29.28 7.22 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.845 0.355 . . . . 0.0 110.991 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.403 ' CD1' ' O ' ' A' ' 5' ' ' ASP . 6.6 m-85 -149.72 87.87 5.03 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.619 179.906 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_exo -43.81 106.46 0.08 OUTLIER 'Trans proline' 0 C--N 1.344 0.34 0 C-N-CA 122.701 2.267 . . . . 0.0 112.712 -179.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.4 p-10 -126.82 -45.17 1.61 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.9 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.504 ' O ' HG12 ' A' ' 9' ' ' VAL . 44.6 t -155.5 59.35 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.906 179.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 144.58 -99.19 0.21 Allowed Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.814 -0.708 . . . . 0.0 112.384 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 1.9 t0 -108.93 -31.96 7.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.741 0.305 . . . . 0.0 110.749 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.32 164.4 13.35 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.735 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 4.7 ttp85 -115.95 173.12 6.73 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.786 0.327 . . . . 0.0 110.875 -179.997 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.665 ' N ' HD13 ' A' ' 14' ' ' ILE . 0.2 OUTLIER -143.43 28.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.181 179.955 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.418 ' HA ' HD13 ' A' ' 15' ' ' LEU . 1.2 mm? -127.26 163.82 23.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.818 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -139.3 -67.39 0.45 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.112 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.114 0 CA-C-O 118.41 -1.217 . . . . 0.0 112.515 -179.951 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.264 0 N-CA-C 112.622 -0.191 . . . . 0.0 112.622 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -72.71 -90.38 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.408 0 C-N-CA 122.414 2.076 . . . . 0.0 112.288 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 4.9 ttpt -90.21 84.66 6.11 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 120.729 0.3 . . . . 0.0 111.027 179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.01 -158.43 7.82 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.661 -0.78 . . . . 0.0 112.635 179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -114.06 -16.71 12.09 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.554 0.216 . . . . 0.0 111.345 -179.85 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -109.33 91.13 9.28 Favored Pre-proline 0 C--N 1.33 -0.24 0 CA-C-O 120.679 0.276 . . . . 0.0 110.806 -179.877 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.434 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 93.7 Cg_exo -43.23 114.52 0.47 Allowed 'Trans proline' 0 C--N 1.347 0.454 0 C-N-CA 122.843 2.362 . . . . 0.0 112.846 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.457 ' OD1' HG23 ' A' ' 9' ' ' VAL . 3.3 p-10 -134.33 -44.84 0.77 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.846 179.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.576 ' O ' HG12 ' A' ' 9' ' ' VAL . 50.0 t -145.15 54.82 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.777 179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 137.68 -92.62 0.21 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.317 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.3 t0 -105.56 -40.99 5.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.814 0.34 . . . . 0.0 110.695 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.434 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 156.76 167.6 18.2 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.686 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 7.7 ptt-85 -106.8 154.58 20.79 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 120.755 0.312 . . . . 0.0 110.766 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 7.9 tp -93.4 -30.9 4.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.193 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.4 mt -108.48 141.15 40.79 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.927 179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -149.93 81.93 1.38 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.096 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.031 0 CA-C-O 118.369 -1.24 . . . . 0.0 112.493 -180.0 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.271 0 N-CA-C 112.586 -0.205 . . . . 0.0 112.586 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -88.34 -77.72 0.0 OUTLIER 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 122.872 2.381 . . . . 0.0 112.422 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 6.0 ttmt -90.14 96.11 10.52 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.785 0.326 . . . . 0.0 111.049 -179.988 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.566 ' HA2' HD12 ' A' ' 14' ' ' ILE . . . -170.06 -161.81 21.22 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.515 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 38.1 t0 -125.93 27.6 6.32 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.798 0.332 . . . . 0.0 111.076 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -147.07 93.53 4.73 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.631 179.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 95.4 Cg_exo -43.18 121.43 2.42 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.73 2.287 . . . . 0.0 112.86 -179.713 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.1 p-10 -143.17 -45.81 0.3 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.82 179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.65 ' O ' HG12 ' A' ' 9' ' ' VAL . 44.4 t -156.13 38.57 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 121.077 0.465 . . . . 0.0 110.619 179.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 163.79 -107.97 0.32 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.364 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -101.5 -30.89 11.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.776 0.322 . . . . 0.0 110.824 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 156.7 165.67 15.18 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.811 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 12.9 ptt180 -126.57 160.17 31.4 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.727 0.298 . . . . 0.0 110.993 179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.638 ' N ' HD13 ' A' ' 14' ' ' ILE . 0.2 OUTLIER -155.51 25.72 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.301 179.803 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.4 mt -141.59 57.24 1.51 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.363 -0.381 . . . . 0.0 110.977 -179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.87 68.9 7.48 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.134 179.94 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.055 0 CA-C-O 118.341 -1.255 . . . . 0.0 112.515 179.934 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.517 0.188 0 N-CA-C 112.626 -0.189 . . . . 0.0 112.626 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_endo -74.73 -93.03 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.454 2.103 . . . . 0.0 112.522 -179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.6 ttpt -90.23 86.47 6.53 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.774 0.321 . . . . 0.0 111.159 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.0 -145.68 4.91 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.467 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -118.95 -25.4 6.27 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.583 0.23 . . . . 0.0 111.573 -179.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -119.1 106.0 43.95 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 116.66 -0.245 . . . . 0.0 111.048 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.483 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 87.4 Cg_exo -46.44 112.95 0.53 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.639 2.226 . . . . 0.0 112.677 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -118.52 -45.35 2.62 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.855 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.584 ' O ' HG12 ' A' ' 9' ' ' VAL . 48.7 t -155.46 54.53 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.766 179.706 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 150.93 -84.35 0.16 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.905 -0.664 . . . . 0.0 112.345 -179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -121.39 -40.03 2.61 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.712 0.292 . . . . 0.0 110.776 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.483 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 160.79 167.08 20.77 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.583 -0.818 . . . . 0.0 112.865 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.3 ptt180 -127.36 152.71 47.13 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 120.758 0.313 . . . . 0.0 110.9 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.542 HD12 ' HG ' ' A' ' 15' ' ' LEU . 1.9 pp -128.25 25.96 2.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.254 179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.561 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.5 OUTLIER -150.06 89.62 1.61 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.872 -179.995 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -127.32 -76.13 0.57 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.096 179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.032 0 CA-C-O 118.424 -1.209 . . . . 0.0 112.534 -179.959 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.284 0 N-CA-C 112.358 -0.297 . . . . 0.0 112.358 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_endo -72.75 -94.35 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.391 0 C-N-CA 122.344 2.029 . . . . 0.0 112.174 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.439 ' O ' HG23 ' A' ' 14' ' ' ILE . 11.1 ttmm -90.53 86.14 6.33 Favored 'General case' 0 C--N 1.333 -0.111 0 CA-C-O 120.714 0.292 . . . . 0.0 111.09 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.11 -155.89 6.63 Favored Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.611 -0.804 . . . . 0.0 112.609 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 12.3 t70 -111.75 -21.82 11.46 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.599 0.238 . . . . 0.0 111.352 -179.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 27.7 m-85 -108.99 92.96 11.62 Favored Pre-proline 0 C--N 1.331 -0.229 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.908 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.458 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 80.2 Cg_exo -45.39 119.18 2.47 Favored 'Trans proline' 0 C--N 1.346 0.429 0 C-N-CA 122.744 2.296 . . . . 0.0 112.793 -179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.765 ' OD1' HG23 ' A' ' 9' ' ' VAL . 4.1 p-10 -135.83 -47.27 0.67 Allowed 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.713 179.703 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.765 HG23 ' OD1' ' A' ' 8' ' ' ASP . 24.9 t -136.81 31.64 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.691 179.697 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.56 -102.28 0.21 Allowed Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.346 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -96.88 -33.53 11.59 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.776 0.322 . . . . 0.0 110.604 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.458 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 157.09 164.47 13.66 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.647 -0.787 . . . . 0.0 112.779 179.756 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -105.23 135.25 46.95 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.748 0.308 . . . . 0.0 110.764 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.439 HG23 ' O ' ' A' ' 3' ' ' LYS . 19.7 pt -86.4 -33.26 7.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.25 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.421 ' HA ' HD22 ' A' ' 15' ' ' LEU . 0.6 OUTLIER -103.57 114.71 29.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.923 -179.931 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -114.35 74.22 0.86 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.013 179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.383 -1.231 . . . . 0.0 112.517 -179.969 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.602 -0.199 . . . . 0.0 112.602 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -74.16 -92.98 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.435 0 C-N-CA 122.494 2.129 . . . . 0.0 112.351 -179.886 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -90.42 86.53 6.48 Favored 'General case' 0 C--N 1.333 -0.126 0 CA-C-O 120.799 0.333 . . . . 0.0 111.006 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -147.2 -154.49 6.23 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.648 -0.786 . . . . 0.0 112.619 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.3 p30 -116.44 -18.2 10.48 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.579 0.228 . . . . 0.0 111.435 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -106.6 98.08 19.2 Favored Pre-proline 0 C--N 1.331 -0.2 0 CA-C-O 120.6 0.238 . . . . 0.0 110.888 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -48.04 112.2 0.55 Allowed 'Trans proline' 0 C--N 1.345 0.377 0 C-N-CA 122.515 2.144 . . . . 0.0 112.673 -179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 1.5 p-10 -134.5 -43.99 0.76 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.872 179.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.547 ' O ' HG12 ' A' ' 9' ' ' VAL . 49.1 t -155.55 56.8 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.923 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 145.2 -104.9 0.33 Allowed Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.686 -0.769 . . . . 0.0 112.564 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -104.4 -31.28 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.792 0.329 . . . . 0.0 110.976 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 164.9 162.68 16.46 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.545 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 11.1 ttp-105 -106.28 165.95 10.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.863 0.363 . . . . 0.0 111.059 -179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 2.7 pt -145.08 32.78 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.988 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 13.7 mt -133.1 95.28 3.51 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.85 -179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -136.18 116.74 13.83 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.113 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.097 0 CA-C-O 118.336 -1.258 . . . . 0.0 112.497 179.979 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.453 -0.203 0 N-CA-C 112.587 -0.205 . . . . 0.0 112.587 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -75.21 -92.27 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.517 2.145 . . . . 0.0 112.449 -179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.618 ' O ' HD11 ' A' ' 14' ' ' ILE . 0.0 OUTLIER -90.41 86.79 6.55 Favored 'General case' 0 C--N 1.333 -0.132 0 CA-C-O 120.689 0.28 . . . . 0.0 111.164 -179.936 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.49 -155.13 6.32 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.567 179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 30.0 m-20 -112.83 -22.38 10.7 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.679 0.276 . . . . 0.0 111.267 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.415 ' CD2' ' N ' ' A' ' 6' ' ' PHE . 4.9 m-85 -112.36 98.67 44.24 Favored Pre-proline 0 C--N 1.33 -0.244 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.909 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 86.3 Cg_exo -47.55 116.06 1.67 Allowed 'Trans proline' 0 C--N 1.346 0.426 0 C-N-CA 122.631 2.221 . . . . 0.0 112.647 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.686 ' OD1' HG12 ' A' ' 9' ' ' VAL . 2.6 p-10 -127.05 -45.0 1.58 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.82 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.686 HG12 ' OD1' ' A' ' 8' ' ' ASP . 14.5 p -157.81 50.88 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.068 179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 159.19 -98.86 0.17 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.392 -179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -124.35 5.12 8.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.567 0.222 . . . . 0.0 111.302 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 129.67 153.57 7.88 Favored Glycine 0 C--N 1.332 0.34 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.749 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 1.6 ptm180 -105.46 152.8 22.56 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.806 0.336 . . . . 0.0 110.79 179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.618 HD11 ' O ' ' A' ' 3' ' ' LYS . 1.1 mp -111.65 -28.99 2.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.175 179.974 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.62 HD22 ' N ' ' A' ' 15' ' ' LEU . 0.1 OUTLIER -107.56 154.43 21.42 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.829 179.957 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -112.11 70.88 0.72 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.085 179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.087 0 CA-C-O 118.341 -1.255 . . . . 0.0 112.474 -179.97 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.41 ' HA3' ' HB3' ' A' ' 13' ' ' ARG . . . . . . . . 0 N--CA 1.452 -0.274 0 N-CA-C 112.703 -0.159 . . . . 0.0 112.703 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -80.07 -92.6 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.438 0 C-N-CA 122.624 2.216 . . . . 0.0 112.438 -179.802 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -90.43 91.37 8.43 Favored 'General case' 0 C--N 1.333 -0.125 0 CA-C-O 120.743 0.306 . . . . 0.0 111.083 -179.991 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.84 -152.75 5.7 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.652 -0.785 . . . . 0.0 112.538 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 14.2 m-20 -112.27 -24.45 9.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.682 0.277 . . . . 0.0 111.204 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -110.66 91.0 11.43 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.776 -179.783 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.446 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 85.4 Cg_exo -44.47 96.28 0.03 OUTLIER 'Trans proline' 0 C--N 1.347 0.458 0 C-N-CA 122.743 2.296 . . . . 0.0 112.642 -179.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.679 ' OD1' HG12 ' A' ' 9' ' ' VAL . 1.7 p30 -96.83 -46.07 6.4 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.679 HG12 ' OD1' ' A' ' 8' ' ' ASP . 14.7 p -146.41 41.25 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.039 179.903 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 157.01 -90.68 0.11 Allowed Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.77 -0.728 . . . . 0.0 112.516 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -108.26 -31.46 7.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.815 0.34 . . . . 0.0 110.891 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.446 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 145.01 170.35 14.01 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.741 179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . 0.808 ' NH2' HD23 ' A' ' 15' ' ' LEU . 1.1 ptm180 -115.88 165.68 12.82 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.83 0.348 . . . . 0.0 110.924 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.405 ' C ' HD12 ' A' ' 14' ' ' ILE . 1.7 pp -114.92 36.37 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.093 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.808 HD23 ' NH2' ' A' ' 13' ' ' ARG . 33.6 tp -108.19 112.12 24.46 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.933 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -90.53 52.17 2.15 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.102 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.073 0 CA-C-O 118.355 -1.247 . . . . 0.0 112.517 179.972 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 N-CA-C 112.783 -0.127 . . . . 0.0 112.783 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -79.59 -91.08 0.0 OUTLIER 'Trans proline' 0 CA--C 1.533 0.451 0 C-N-CA 122.562 2.175 . . . . 0.0 112.592 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -90.43 90.17 7.91 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.679 0.276 . . . . 0.0 111.237 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -146.81 -155.36 6.5 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.604 -0.808 . . . . 0.0 112.42 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . 0.405 ' OD2' ' CE2' ' A' ' 6' ' ' PHE . 1.4 p30 -112.37 -23.26 10.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.785 0.326 . . . . 0.0 111.12 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.405 ' CE2' ' OD2' ' A' ' 5' ' ' ASP . 17.9 m-85 -108.45 96.0 17.77 Favored Pre-proline 0 C--N 1.33 -0.248 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.035 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 78.3 Cg_exo -47.83 110.06 0.28 Allowed 'Trans proline' 0 C--N 1.345 0.388 0 C-N-CA 122.519 2.146 . . . . 0.0 112.44 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.798 ' OD1' HG12 ' A' ' 9' ' ' VAL . 1.5 p30 -115.51 -43.9 3.01 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.999 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.798 HG12 ' OD1' ' A' ' 8' ' ' ASP . 12.7 p -157.84 34.77 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.059 179.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 178.05 -100.59 0.14 Allowed Glycine 0 N--CA 1.45 -0.38 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.504 -179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -111.11 -28.71 8.18 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.714 0.293 . . . . 0.0 111.05 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 168.04 163.68 22.4 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.597 -0.811 . . . . 0.0 112.862 -179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.36 175.04 5.6 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.841 0.353 . . . . 0.0 110.931 -179.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 30.2 mm -114.12 -38.85 2.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.024 179.769 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -122.92 105.58 10.11 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.899 179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -135.1 111.47 9.76 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.059 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.088 0 CA-C-O 118.38 -1.233 . . . . 0.0 112.551 179.984 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . 0.542 ' HA2' HG12 ' A' ' 9' ' ' VAL . . . . . . . . 0 N--CA 1.453 -0.209 0 N-CA-C 112.652 -0.179 . . . . 0.0 112.652 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -78.42 -93.63 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.447 0 C-N-CA 122.58 2.187 . . . . 0.0 112.228 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -90.61 91.13 8.29 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-O 120.775 0.322 . . . . 0.0 111.098 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.07 -159.09 8.38 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.471 179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.47 -20.92 12.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.649 0.261 . . . . 0.0 111.189 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -111.31 92.76 16.7 Favored Pre-proline 0 C--N 1.33 -0.255 0 CA-C-N 116.451 -0.34 . . . . 0.0 110.726 -179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . 0.409 ' HA ' ' HA2' ' A' ' 12' ' ' GLY . 80.5 Cg_exo -45.39 127.82 9.6 Favored 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 122.694 2.263 . . . . 0.0 112.665 -179.789 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.433 ' OD1' HG12 ' A' ' 9' ' ' VAL . 3.0 p-10 -139.81 -46.05 0.44 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.938 179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.605 ' O ' HG22 ' A' ' 9' ' ' VAL . 14.8 p -147.55 38.78 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.971 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 162.08 -90.15 0.11 Allowed Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.795 -0.716 . . . . 0.0 112.491 -179.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -116.54 -39.19 3.37 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.857 0.36 . . . . 0.0 110.778 179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.409 ' HA2' ' HA ' ' A' ' 7' ' ' PRO . . . 171.53 160.77 20.85 Favored Glycine 0 N--CA 1.45 -0.391 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.592 179.969 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -111.93 -179.07 3.59 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.871 0.367 . . . . 0.0 110.948 179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.445 HD12 ' C ' ' A' ' 14' ' ' ILE . 2.2 pp -143.89 27.34 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.126 179.848 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.57 ' H ' HD23 ' A' ' 15' ' ' LEU . 1.3 pt? -150.03 121.68 8.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.942 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -150.06 -170.27 3.6 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.11 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.081 0 CA-C-O 118.374 -1.237 . . . . 0.0 112.503 -179.979 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.273 0 CA-C-O 120.351 -0.138 . . . . 0.0 112.781 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -75.58 -90.66 0.01 OUTLIER 'Trans proline' 0 CA--C 1.532 0.42 0 C-N-CA 122.566 2.178 . . . . 0.0 112.504 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -90.38 86.74 6.55 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 120.738 0.304 . . . . 0.0 111.179 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -149.05 -158.87 8.27 Favored Glycine 0 N--CA 1.452 -0.234 0 C-N-CA 120.659 -0.781 . . . . 0.0 112.54 179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -112.02 -17.11 12.93 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.566 0.222 . . . . 0.0 111.343 -179.797 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 49.2 m-85 -108.69 92.67 10.67 Favored Pre-proline 0 C--N 1.331 -0.23 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.896 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_exo -46.4 116.45 1.56 Allowed 'Trans proline' 0 C--N 1.345 0.389 0 C-N-CA 122.547 2.165 . . . . 0.0 112.63 -179.822 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . 0.743 ' OD1' HG12 ' A' ' 9' ' ' VAL . 2.3 p-10 -131.95 -45.58 0.95 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.927 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.743 HG12 ' OD1' ' A' ' 8' ' ' ASP . 12.1 p -154.65 46.21 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.985 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 161.81 -103.12 0.22 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.809 -0.71 . . . . 0.0 112.323 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -110.06 -25.97 9.95 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.725 0.298 . . . . 0.0 110.907 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 159.56 162.7 12.4 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.691 179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -102.77 171.17 7.56 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.749 0.309 . . . . 0.0 110.811 179.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.498 HG23 ' N ' ' A' ' 15' ' ' LEU . 7.5 tp -146.43 -45.33 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.09 179.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.498 ' N ' HG23 ' A' ' 14' ' ' ILE . 0.9 OUTLIER -114.83 121.21 42.56 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.765 -179.951 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -107.53 30.79 5.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.196 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.082 0 CA-C-O 118.382 -1.232 . . . . 0.0 112.522 179.943 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.518 0.255 0 N-CA-C 112.758 -0.137 . . . . 0.0 112.758 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' PRO . . . . . 0.428 ' O ' ' N ' ' A' ' 12' ' ' GLY . 60.2 Cg_endo -75.67 -91.07 0.01 OUTLIER 'Trans proline' 0 CA--C 1.533 0.457 0 C-N-CA 122.595 2.197 . . . . 0.0 112.565 -179.816 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.461 ' O ' HD11 ' A' ' 14' ' ' ILE . 1.1 ttpt -90.52 86.73 6.5 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.621 0.248 . . . . 0.0 111.15 -179.956 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -137.23 -97.56 0.46 Allowed Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.559 -0.829 . . . . 0.0 112.625 179.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -171.32 -37.77 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.892 0.377 . . . . 0.0 110.715 -179.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -105.65 97.46 14.68 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.435 179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 80.5 Cg_exo -40.92 111.18 0.14 Allowed 'Trans proline' 0 C--N 1.347 0.484 0 C-N-CA 122.902 2.402 . . . . 0.0 112.957 -179.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASP . . . . . . . . . . . . . 3.6 p-10 -116.08 -47.17 2.78 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.859 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' VAL . . . . . 0.609 ' O ' HG12 ' A' ' 9' ' ' VAL . 29.2 t -155.61 41.9 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.859 179.796 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 169.83 -81.73 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.531 -179.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -128.95 -45.48 1.27 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.808 0.337 . . . . 0.0 110.928 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 2' ' ' PRO . . . -176.79 154.03 15.29 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.687 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.41 174.44 5.91 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.871 0.367 . . . . 0.0 111.041 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.572 ' O ' HG22 ' A' ' 14' ' ' ILE . 18.3 mt -132.6 32.34 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.096 -0.502 . . . . 0.0 111.063 179.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.0 mt -131.99 156.55 46.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.897 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -137.33 152.19 49.45 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.066 -179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.043 0 CA-C-O 118.373 -1.237 . . . . 0.0 112.514 179.975 . . . . . . . . 0 0 . 1 stop_ save_